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Detoxification enzymes play an important role in cleaning the body from the toxins. These 
ones represent a hindrance to some drugs to fulfill their tasks, especially active compounds like 
anti-cancer drugs. These latter are considered to have a high degree of toxicity in the body, which 
makes them targeted by the previous enzymes. 
We refer in this study to GSTp1-1, which is included in the detoxification enzymes class II 
targeted by NBD derivatives. It has dual defense feature, namely: inhibition GSTp1-1 and prevent 
the formation of each of the following complexes JNK1-GSTp1-1 and theTRAF2-GSTp1-1, that 
causes prolonged stopping of the cell cycle and facilitates apoptosis of damaged cells. 
This is what made us in this study shed light on the modeling similar compounds, and to 
achieve this goal, we applied a set of methods adopted in the modeling of active materials of high 
biological quality. Among them, the QSAR Two-dimensional (2D-QSAR) coupled with a virtual 
examination, by using a technique similarity search. In addition, we concretized a three - 
dimensional stereo (3D-QSAR) which contains effective biological properties (Pharmacophore). 
This application resulted to determine a quantity of compounds bearing the same previously 
identified characteristics. Therefore, we put limits, selectivity features extracted from specialized 
references, to reduce and identify biologically the best. We make sure of the validity and safety of 
extracted models mentioned above by using several ways, namely:  LOO-CV, external test set 
validation, fisher randomization, and cost analysis. 
As a final result of this research, we identified 28 new derivatives of NBD From both 
studies, at different inhibitory concentrations, micromolar unit (µM); the value of the half-maximal 









حيث تمثل عائقا . يف الجسم من السموم المتعرض لهادورا هاما في تنظ ،تلعب انزيمات ازالة السمية
تعتبر هذه نجد المضادات السرطانية.  (المركبات الفعالة) من بين هذه االدوية ،لبعض االدوية في تادية مهامها
 من قبل االنزيمات المشار اليها سابقا. ما يجعلها مستهدفة، رة ذات درجة سمية عالية في الجسماالخي
، التي تندرج ضمن انزيمات ازالة السمية من الدرجة الثانية GSTp1-1الى  ،نشير في هذه الدراسة
منع و GSTp1-1المتمثلة في تثبيط  ع،ية الثنائية للدفاذات الخاص -NBDالتي تستهدف من طرف مشتقات و
التي تتسبب في توقيف دورة الخلية  TRAF2-GSTp1-1و JNK1-GSTp1-1 :تشكل كل من المعقدات التالية
 لفترات طويلة وتسهيل استماتة الخاليا التالفة.
 منه، جولتحقيق الهدف المر ته الدراسة نسلط الضوء على نمذجة اشباه هذه المركبات.اهذا ماجعلنا في ه
 ـتقنية ال، جودة بيولوجية عالية. نذكر منها لة ذاتفي نمذجة مواد فعا ،قمنا بتطبيق مجموعة من المناهج المعتمدة
QSAR 2)ثنائية االبعادD-QSAR)  باستخدام تقنية  ،مقرونة بالفحص الظاهريsimilarity search اضافة .
بيولوجية ذات قيمة  (ميزات) يحوي خصائص.  (3D-QSAR)يد مجسم ثالثي االبعادجسنا بتالى ذلك قم
 ،المحددة سابقا لميزاتهذا التطبيق عل تحديد كم من المركبات الحاملة لنفس ا . اسفر (pharmacophore)فعالة
لتقليل وتحديد االحسن من الناحية ، -تقائية مستخلصة من مراجع متخصصةمعايير ان- ض الحدودعماجعلنا نضع ب
م عدة طرق نذكر باستخدا ،وسالمة النماذج المستخرجة والمذكورة اعاله مصداقيةالتاكد من بالبيولوجية. قمنا 
 .LOO-CV, external test set validation, fisher randomization, cost analysisمنها 
ة تمن كال البحثين بتراكيز تثبيطية متفاو، NBD لـ دايمشتقا جد 28حددناكنتيجة نهائية لهذا البحث 
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Since the 20th century, the increase of life expectancy has been associated to the increase in 
exposure to carcinogenic elements, particularly those in tobacco smoke, as: azo dyes, aflatoxins, 
asbestos, benzene and radon, as well as ionizing radiation. These causes have been well 
documented as leading to a wide range of human cancers. Therefore, this disease has become the 
second most common cause of death around the world  [1].  Nevertheless, there is a way to fight 
against cancer. These often-complementary therapies are used individually or in conjunction, 
depending on the type, position and stage of the cancer. There are mainly three kind of treatment 
such as: Chemotherapy, radiotherapy and surgery [2].  
Chemotherapy occupies an important place in the clinical treatment of cancer. It uses such 
medications to destroy cancer cells or stop them from developing and spreading to other areas of 
the body. Many drugs are used in the treatment of cancer diseases; sometimes, however, they 
cannot play their role due to the detoxifying enzymes, like glutathione S-transferases (GSTs), 
which attacks these drugs and reduce their therapeutic effect. GSTs are a family of massive, 
distributed phase II detoxifying enzymes, which catalyze the recombination of reactive 
 
 
Chapter I: Introduction                                    DR. ALMI Imane 
 
2 
electrophiles to the nucleophilic sulfur of the main intracellular thiol. GSTs’ inhibitors have been 
shown to decrease drug resistance by improving anti-cancer drug action in tumor cells [3, 4]. 
Several synthesized compounds have been used to suppress detoxifying enzymes, including 
Nitrobenzoxadiazole (NBD) compounds (Scheme 1) and their derivatives, which gained a 
significant attention due to their unique mode of action: at the cellular level, they induce the 
dissociation of the JNK1- GSTP1-1 and TRAF2-GSTP1-1 complexes (GSTP1-1 for glutathioneS-
transferase), leading to prolonged cell cycle arrest and apoptosis [5, 6]. 
Figure I. 1: The basic skeleton of Nitrobenzoxadiazole. 
Drug discovery is a long and complex process [7], both in terms of time and money invested  
[8]. The field of "drug design" can be explored through molecular modeling, using computer tools 
to design of new molecules  [9]. It essentially boils down to identify new compounds (natural or 
synthetic molecules) which will ideally evolve into drugs acting on specific biological targets 
responsible for dysfunctions. The identification of therapeutic targets is linked to knowledge of 
molecular functioning, metabolic pathways and generally biological systems, and the cause of 
disease [10]. 
The world of pharmaceutical research is constantly optimizing all stages of its drug 
discovery and development process. Chemoinformatics is a tool of choice for reducing the time 
and cost of developing a drug. This discipline can intervene at different levels of the drug discovery 
process. Among the chemoinformatics techniques, we can cite the screening of chemical libraries 
(QSAR, docking and pharmacophores techniques). Chemoinformatics is present today in all stages 








Chapter I: Introduction                                    DR. ALMI Imane 
 
3 
By analogy with the expressions in vivo and in vitro, the term “in silico” has been 
introduced to qualify the numerical methods used to treat such systems. By its name, this term 
refers to silicon, the main material found in all computers’ chips. The in silico field brings together 
a very large set of numerical methods based on the laws of physics and chemistry which, using 
mathematical approaches, make it possible to simulate or model a biological phenomenon using 
the computer tool. Virtual screening is the most widely used in-silico strategy for the identification 
of compounds in the context of new drug research [12]. 
The advantage of virtual screening "in-silico" is therefore to provide a small list of 
molecules to be experimentally tested, thus reducing costs and saving time. We can also quickly 
explore many molecules and then focus, at the experimental level, on the most interesting 
molecules [13]. 
I.1. Contributions: 
The objective of our work is to use virtual screening methods in the search for new bioactive 
molecules and to study their interactions with the enzyme glutathione-S-transferase. 
Our main contributions are summed in these essential points, namely: 
 Multiple Linear Regressions (MLR) and Artificial Neural Network (ANN) were applied 
for modeling of the studied molecules. 
  Developed ANN models have reasonably predicted the GSTP1-1 inhibitory activities of 
23 hits. 
 Generation of a pharmacophore model based on ligands. 
  Virtual screening procedure has been applied to large chemical compound database. 
 Hits obtained have good predictive activities. 
 Molecular docking of molecules resulting from virtual screening. 
 I.2. Organization of the dissertation: 
To achieve our goal, we have organized our thesis into three chapters:  
1. Part I- Background on cancer disease and drug discovery: In the chapter II we Will 
introduce the fundamental principle, the possess of development and discovery of drugs. In 
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2. Part II-Computer-Aided Drug Design and Discovery: this chapter consists of two parts: 
Ligand-based drug design (LBDD) and Structure-Based Drug Design (SBDD), which 
describe principle formulation, theories of the methods used during this research and the 
principle equations for each method. 
3.  Part III- Contributions and result: we will be mainly dedicated in this part to 
interpretations of the results obtained, which were divided into two parts. The first one, a 
Quantitative structure-activity relationship (QSAR) models were generated using Multiple 
Linear Regression (MLR) and Artificial Neural Network (ANN). These technics aim to 
determine the best molecular descriptors to be used in conjunction to identify the best 
candidates for GSTP1-1 inhibition. At last, the obtained QSAR models were employed to 
define biological activities of potentially novel active compounds by means of in silico 
screening processes. As to the second part, Ligand-based pharmacophore modeling was 
used to identify the chemical features responsible also for inhibiting GST p1-1. The 
identified features used to screen the database contain more than 200000 compounds. The 
last point consists of a molecular docking analysis, which recognizes that leads are possible 
toward the GST p1-1 enzyme and reveals the lowest energy and good associations with 
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“God has created all diseases, and he also has created an agent or a drug for every 
disease. They can be found everywhere in nature, because nature is the universal 
pharmacy. God is the highest ranking pharmacist.” the Swiss-Austrian medical doctor 























Background on cancer disease 




II.1. Life cycle of a drug: 
Throughout history, there was an almost continuous need for clinical action in the 
treatment of illness. There was no possibility to understand the biological origin of these 
diseases. The notion that treating diseases or alleviating effects might be done by smoking, 
consuming or adding morphine, ephedra, hemp, tobacco, salicylic acid, digitalis, coca, quinine, 
and a number of other medications, still in use, for a long time [1, 2]. The identification of new 
drugs was primarily done by changing the molecular structure of an existing drug or by 
serendipity. Whereas this process was a slow trial, it gives results with many errors. The 
techniques used to discover medicinal agents have evolved significantly over the course of 
human history. Now, a computer can display the molecular structure of any drug from a list of 
thousands in a database [3]. Computer Aided Drug Design (CADD) is expressed by in silico 
term; as an analogy to the Latin phrases in situ, in vitro and in vivo. This means the logical 
design from which medications are formulated or found using computational methods. The 
main aim of in silico Aided Drug Design is to identify the best chemical compound to 
experimental testing by reducing late stage attrition and costs [4]. 
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The word "lifecycle" refers to the sequence of modifications that a substance, process, 
activity, … etc has experienced over its lifetime. A drug’s lifecycle includes two major steps, 
namely: research and development (R&D) that brings a new drug from discovery to launch, 
and the marketing and sales of medications [5]. In this part, we aim to describe the four major 
disciplines which have completely revolutionized the search for new drugs and resulted in the 
processes currently used in the early stages of research and development (R&D).  
 The drug discovery R&D processes are highly costly, time consuming and technology 
intensive. They bring together all the steps leading to the marketing of the new drug. According 
to published studies, it is expected that only one in ten of the compounds entering clinical 
development is successful, with an overall cost of USD 500-800 million and a standard time 
scale of 10-15 years from pre-clinical development to regulatory approval. Usually, the whole 
process is divided into "Discovery," "Development" and "Registration" stages (Figure II.1) 
[6, 7].   
 
 
Figure II.1. Overview of the process of drug discovery and development.   
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Drug analysis can be divided into a variety of smaller tasks and roles. The mechanism 
can be systematically separated into two different parts at the highest level, namely: discovery 
and development [8]. Drug discovery is a lengthy arduous method. It is broadly packaged with 
biological target recognition and associated disease, target validity, high throughput 
identification of hits and leads, lead optimization, and preclinical and clinical analysis [9]. Each 
step of drug development should aim to create a scientific connection between a biological 
target (e.g.: enzyme, ion channel, G-protein-coupled receptor, etc.) and a disease-state model 
designed to simulate human disease. Drug development aims to evaluate the safety/toxicity and 
efficacy of new drug substances. The key aim of drug production is to create a research database 
that confirms the potency and safety profile of the drug and its dose regiment(s) for marketing 
purposes [8]. 
Early stages in drug discovery are the initial process of target identification and progress 
to the later phase of lead optimization. Many resources, including the private market, clinical 
work and academic research, assist in identifying the best disease target. The selected target is 
then used by the pharmaceutical industry and more recently by several research centers to select 
molecules for the production of suitable drugs. The process requires a numerous early stages 
[10]. 
We will describe the four principal stages drug research: (i) target determination, (ii) 
model establishment, (iii) discovery of lead compounds, and (iv) optimization of the lead 
compounds. 
II. 1. 1. Target identification and Validation 
Target identification and validation are the starting point of new drug R&D process 
where the method of selecting a potential drug candidate starts, with the determination of a 
disease state that can be solved or changed by the use of effective chemotherapeutic action [11, 
12]. Once the disease has been defined, the next step is to identify a potential biological target. 
A good target needs to be active, safe, meet clinical and business needs and, most importantly, 
be ‘druggable’. A 'druggable' target is accessible to a putative drug substance, i.e. a small 
molecule or larger biologics and, upon binding, generates a biological response that can be 
measured both in vitro and in vivo [13]. Following identification of the drug target, a systematic 
validation should show that a molecular target is directly involved in a disease process, and that 
modulation of the target is likely to have a therapeutic effect [10]. Good target selection and 
verification encourages improved confidence in the interaction between target and disease, and 
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enables them to explore where target modulation can contribute to mechanism-based side 
effects [13]. 
II. 1. 2. Hit identification: 
Following the process of target identification, hit identification aims to identify where 
the small molecule Hits suitable for use in a medical environment. Of course, this comparatively 
simple statement is actually a representation of an extremely complex and multi-faceted 
problem. To identify the small molecule (hits), there are some variety of screening paradigms 
exist that have been developed in order to provide some guidance as to look for biologically 
useful molecules. Among these paradigms, we mention: firstly, High Throughput Screening. 
The primary role of HTS is to detect lead compounds and supply directions by testing, in an 
automated fashion, for activity as inhibitors (antagonists) or activators (agonists) of a particular 
biological target. Secondly, Virtual Screening [14-16]. Virtual screening or VS is an alternative 
method to the computational screening of large chemical libraries. It is a modern technique 
attracts an increasing degree of interest in the pharmaceutical industry as a productive and cost-
effective technology in the quest for novel lead chemicals substances [17, 18]. 
In view of their activity, but also of additional criteria such as their originality or their 
stability, the compounds to become drugs are most likely selected as hits and then optimized 
[17, 18]. 
II. 1. 3. Lead generator and optimization: 
 The goal of this stage of the work is to change each hit list in order to try to produce 
more potent and selective compounds by iterative synthesis and to analyze their efficacy in any 
available in vivo models (Figure II.2). In each step of the "lead optimization" process, new data 
are created as adjustments in the molecular structure of the "lead". These details are used to 
develop the next generation of compounds. This step of generating Structure-Activity 
Relationship data persists until appropriate chemicals substances have been developed for 
clinical assessment [1]. All these chemical modifications around a common scaffold aimed to 
elucidate SAR, to establish consistent correlations of structural features, or groups, with the 
biological activity of compounds in a given biological assay. This SAR aimed to maximize 












Figure II. 2. The lead optimization phase start with the detection of the lead structure ('hit') in the 
relevant biological assay. New analogs with surface changes are prepared and tested in the bioassay. If 
the outcomes of the assay increase, the modifications are retained and the cycle is repeated. If the 
modifications are negative, the modifications are eliminated and the cycle is repeated. This method 
proceeds until a potential substance with the desired properties has been identified [1]. 
 
II. 1. 4. Preclinical studies: 
Following a series of in vitro and in vivo experiments to find out the best drug candidate 
and before clinical trials, preclinical studies try to provide information on the preparation 
process, protection, dosage, acute and chronic toxicity, allergic reactions, formulation and 
components, pharmacokinetics, stability, effectiveness, mutagenicity and local irritation tests, 
hemolytic, reproductive toxicity, and so on and so forth [2]. Preclinical studies must comply 
with the guidelines, laid down by Good Laboratory Practice to ensure consistent results and 
required by authorities, such as the FDA, before submitting an IND approval [21]. 
The clinical phases I, II, III, and IV studies consist to evaluate drug safety for human 
beings, with a small and a large group of participants, and identify the dose range and side 
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Table II.1. The clinical and preclinical trials in drug development [21] 
 
II. 2. Cancer: 
The human body is made up of over than 60000 billion cells. These are the units which make 
up tissues and then our organs, including heart, liver and lungs. If the body wants, our cells are 
doubled to destroy any cells that are damaged or their lifetime is ended. This makes it possible 
for our tissues to retain their shape and function with the flow of time. Therefore every cell is 
conditioned to multiply and die. This organized but complex program is regulated by the center 
of the cell, the nucleus, which includes chromosomes containing several genes made up of 
DNA. At times, few any of these genes are modified. The nucleus gives out irregular orders, 
and the cell goes incorrect. It multiplies abnormally, taking on a life of its own; each new cell 
generated contains the same error. Cells proliferate chaotically to form a tumor. This period 
may be short, but it is always 10 to 30 years long and may distinguish the birth of the first 
irregular cell from the creation of a tumor of around one cubic centimeter in which several 
blood vessels are formed to survive, which will supply the tumor with oxygen and nutrients, 
allowing it to survive and developed. That's what we call the concept of angiogenesis. However 
the tumor is only really risky when cancer cells start to invade the surrounding regions through 
the vessels and spread to the surrounding organs. These cells can then invade other parts of the 
body to multiply and generate new cancer cells. Metastasis is the word used for this process of 
spread. But why does a cell become cancerous? In addition, is there a treatment for it? 
II. 2. 1. Cancer, a major health issue:  
 Cancer is a vast family of diseases caused by irregular cell formation, growth rate and 
capacity to invade other organs [22]. Every sixth death in the world is due to cancer, making it 
the second leading cause of mortality worldwide. World health organization estimated that 42 
Contents Preclinical trials Clinical trials 
Phase I Phase II Phase III Phase IV 
Objects Lab study  
In vitro assays 
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million people around the world suffered from different types of cancer cells. This percentage 
has more increased since 1990, when an estimated 19 million patients had cancer, with an 
approximate 9.6 million patients dying from cancer during 2017 (Figure II.  3). Thus, cancer is 
a significant issue impacting the welfare of all human cultures [23, 24]. Unfortunately, it is a 
form of disease at the stage of the tissues and this variation is a significant problem for its 
particular diagnosis, followed by the effectiveness of the medication [25, 26]. Cancers as a 
whole accounted for 30.0 per cent of man deaths and 24.8 per cent of woman deaths in 2015. 
When viewed independently, 4 of the 10 leading causes of death of both sexes were cancers. 
Lung, colorectal cancer, leukemia and lymphomas are among top leading causes of mortality 
for both genders. Breast cancer is the most common type of cancer among female accounting 
for about 30% of all woman cancers [27]. Over the last 10 years, the incidence of breast cancer 
has increased by 1.5 per cent per year. Mortality, however, does not rise. Prostate cancer 
accounts for approximately 35% of all male cancers. The occurrence has risen by an average of 
4% annually over the last 10 years, primarily due to early detection. However, the increase in 
prevalence is not followed by an increase in mortality [28, 29]. 
 
 
Figure II. 3 improvement in three cancer survival measures, World, 1990 to 2017. This graph measures 
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Recently, scientists summarized the ten biological hallmarks of cancer (Figure II. 4) as 
sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling 
replicative immortality, inducing angiogenesis, activating invasion and metastasis, avoiding 
immune destruction, tumor promoting inflammation, deregulating cellular energetic, genome 
instability and mutation [30].  
 
 
Figure II. 4 Preventive targeting of cancer hallmarks [30]. 
Medications, which interact with acquired ability required for cancer cells growth and 
development, have been developed, incorporated in clinical trials or, in certain cases, licensed 
for clinical use in the treatment of some types of human cancer. In contrast, the investigational 
medicines are designed to target one of the enabling characteristics and evolving features shown 
in Figure II. 4, which still retain promise as cancer treatment. Drugs mentioned are just 
illustrative examples; for each of these hallmarks, there is a deep pipeline of candidate drugs 
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II. 2. 2. Pathogenesis of cancer: 
Cancer has been developed for many years and has several causes. These ones can exist 
in varying degrees, both inside and outside of the body, to contribute to the development of 
cancer [31]. Knowing the causes of cancer offers a basis for recognizing the potential for cancer 
prevention. If a reason is known, it is much easier to know whether it can or cannot be easily 
avoided [32]. Scientists typically divide these factors into two categories: those inside the body 
and those outside the body; environmental factors. It is estimated, however, that only 5-10 per 
cent of cancer is caused by inherited traits and the remaining 90-95 per cent is either caused or 
sustained by environmental factors Figure II. 5 [33]. 
 
Figure II. 5 The effect of genes and the environment on cancer growth. (a) The percentage 
contribution of genetic and environmental causes to cancer. (b) The figure reflect family risk ratios-the 
age-adjusted risk ratio for first-degree cases compared to the general population. (c) The number of 
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II. 2. 2. 1. Outside Body Factors (Environmental Factors): 
Exposure to a wide range of natural and man-made chemical compounds in the 
environment accounts for at least two thirds of all cancer cases worldwide. These external 
factors involve lifestyle habits, such as: unhealthy diet, excessive alcohol intake, cigarette 
smoking, excessive exposure to sunlight, lack of exercise, and increased exposure to some 
viruses. Other considerations include exposure to certain pharmaceutical products, viruses, 
radiation, hormones, bacteria and environmental contaminants that may be present in the air, 
water, food and the workplace. Analysis of occupational groups with greater exposures to these 
chemicals compared to the general population has identified the cancer dangers related with 
certain environmental chemical agents [31]. 
II.2.2.2. Inside Body Factors: 
Many conditions inside the body make certain individuals more likely to develop cancer 
than others. For example, certain individuals either inherit or develop the following conditions: 
changed genes in the cells of the body, increased hormone levels in the bloodstream, e.g. 
estrogens, which are supposed to contribute to human breast cancer, and testosterone and its 
metabolites are the cause of human prostate cancer or compromised immune systems, e.g. in 
the case of Severe Combined Immune Deficiency (SCID). Some of these factors can make 
some people more susceptible to cancer disease [31].  
II.2.3. Treatment of cancer: 
There are however means to combat cancer disease. These complementary therapies are 
sometimes used on their own or in conjunction, depending on the type of cancer and its status. 
The purpose of these therapies is to make possible to remove the tumor and heal a patient with 
early stage cancer or like a chronic disease in order to monitor its growth. Common and newer 
forms of medication (surgery, radiation therapy, chemotherapy, targeted therapy, and 
immunotherapy) are predominantly associated with adverse outcomes which have a detrimental 
impact on quality of life. Thus, the battle for more successful, more tolerable anti-cancer 
therapy continues [34]. 
Chemotherapy is known to be the most effective and commonly used modality in most 
forms of cancer. Tumor cells have an improved capacity to divide and the standard of 
immortality because they are not controlled by apoptosis. Cell proliferation to cell death ratio 
is therefore high. Chemotherapy prevents tumor growth by killing off their ability to divide and 
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enforce apoptosis. The two branches of the chemotherapeutic drugs are also cytostatic 
(biological drugs) and cytotoxic [35]. 
II. 2. 3. 1. Glutathione-S-Transferase (GST): 
 Living organisms are constantly exposed to exogenous and endogenous toxic chemical 
species, which can cause harmful and often lethal effects. The ability of living organisms to 
survive the danger posed by such compounds is a fundamental biological adaptation for 
survival. Cells have implemented various methods to combat the effects of toxic substances and 
their metabolites. In this context, special enzymatic and non-enzymatic mechanisms are in place 
to protect cells from the destructive effects of toxic chemical species. Detoxification enzymes 
have a crucial function to play; making them less biologically active, more water-soluble and 
more easily removed from the body. Among others, the GST target was chosen for our analysis. 
Figure II.6 reflects the GST detoxification mechanism [36, 37]. 
Figure II. 6 Overview of xenobiotic enzymatic biotransformation. Harmful molecules can migrate 
through the plasma membrane and, within the cells, may be attacked by the enzymes of the so-called 
Step I metabolism. The major ones belong to the Cytochrome P450 family, consisting of many enzymes 
that catalyze various reactions, including hydroxylation— the main reaction involved—oxidation and 
reduction. GSTs that catalyze the conjugation of phase I-modified xenobiotics to endogenous GSH play 
a key role in the resulting phase II metabolism. The conjugate obtained is then actively transported out 
of the cell by various transmembrane efflux pumps (Phase III). Any compounds can join the metabolism 
of phase II directly [37]. 
GSTs have many biological functions to play. They were defined as the most important 
enzymes involved in the metabolism of electrophilic compounds. They are classified as a family 
of phase II detoxification enzymes that metabolize a broad range of xenobiotic and end-of-
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obiotic toxic compounds, which were classically defined as catalyzing the conjugation of 
glutathione (GSH) to electrophilic compounds through thio-ether linkages [38, 39]. 
 GSTs are 50 000 Da, they are proteins formed by homodimers or heterodimers, each 
monomer has an active center consisting of 210 amino acids and two binding sites: A G-site in 
which glutathione (GSH) is bound and an H-site for an electrophilic substrate [40]. The GST 
detoxification reaction occurs by the following mechanism (Figure II. 7). In eukaryotes, there 
are three distinct families of GSTs separated by their cellular location: cytosolic, mitochondrial 
and microsomal (also known as membrane-associated proteins in eicosanoid and glutathione 
metabolism or MAPEG) [41]. Cytosolic GSTs are the most complex and closely related to the 
development of human diseases and are distributed and categorized into seven subtypes on the 
basis of their chemical, physical and structural properties. These subtypes are α, π, μ, θ, ω, σ, 
and δ. The cytosolic α, π, and μ classes are abundant and the most widely studied GST classes 
[37]. 
 
Figure II. 7 (A) GST detoxification process. (B) (left) GSH identification GST. (right) The molecular 
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II. 2. 3. 2. GST P1-1: 
II. 2. 3. 2. 1. GST P1-1 physiological function (Role in cancer diseases): 
The resistance of various human tumors to anti-cancer agents has been specifically 
associated with the conjugation of GST enzymes to GSH and the over expression of these 
enzymes. GSTs are implicated in resistance to many anticancer drugs in a wide spectrum of 
cancers. GST Pi (GSTP1-1) is the most prevalent, widely studied and highly expressed in 
several types of cancer cells (especially pancreatic, non-small cell lung, colon, liver, ovarian, 
breast, and lymphoma). Over expression of GSTπ can contribute to the defense of cancer cells 
against an attack by anticancer drugs. In which, tumor cells use GSTπ to form a GSH – X 
complex between antitumor drugs and GSH; the complex is excreted by Pgp and MRP out the 
cell. Synergistic interactions between GSTs and Pgp or MRPs are guiding the production of 
multidrug resistance in tumor cells [37, 43].  
Recent literature has established GSH and other associated metabolic enzymes as 
essential to the cells safety from ROS via oxidation and redox mechanisms [46, 47]. Its 
enzymatic function is based on two aspects: the catalytic activity of Cys47 and Cys10, and the 
auto-S-glutathionylation of Cys47 and Cys10, both of which disrupt the subsequent interaction 
with C-Jun NH2-terminal kinase (JNK), causing the formation of a GSTπ multimer. Other 
members of the GSH-redox system, such as glutamate cysteine ligase, glutathione peroxidase 
and glutathione reductase, also play a significant role in this phase [46, 47]. 
In addition to metabolite detoxification, the first GSTπ described was initially defined 
as ligand binding properties due to its ability to interact covalently and non-covalently with 
different compounds, resulting in inhibition of conjugation activity [48]. GSTπ can induce 
cellular apoptosis by activating MAPK, MKK4, downstream JNK-signal components and p38 
kinase, in the setting of cellular stress. Normal cells have low basal JNK activity to maintain 
optimum cell growth conditions. However, in the presence of oxidative or nitrosative stress, 
GSTπ  can form homodimers to alter the reduced state of cysteine residues in its structure, 
resulting in JNK dissociation from the hetero-GSTπ  – JNK complex and ensuing the 
subsequent activation of the c-Jun protein. These sequences of reactions will ultimately cause 
apoptotic pathways (Figure II. 8) [49, 50]. Further research suggests that GSTπ can affect the 
MAPK direction through both JNK and TRAF2 modulations [51]. 
 
 




Figure II. 8 Ligand-binding features of JNK and TRAF2.  
Notes: During physiological conditions, cells have low JNK activity. JNK is sequestered in the shape of 
a GSTπ–JNK protein complex. GSTπ is disassociated from the GSTπ–JNK complex due to oxidative 
stress caused by the administration of medications, resulting in the aggregation of GST oligomers. This 
results in c-Jun phosphorylation and/or ATF2 activation, and this progress also affects downstream 
activities as well. Meanwhile, the recruitment of TRAF2 to the plasma membrane promotes the 
development of ROS. Subsequent oxidation of the previously inactive ASK1–Trx complex causes 
dissociation of the molecule ASK1. TRAF2 then binds to ASK1 to activate the ASK1–JNK signal 
cascade. However, owing to high expression in tumor cells, GSTπ serves as an endogenous negative 
regulatory switch by forming JNK complexes, preventing TRAF2–ASK1 interactions, and eventually 
inhibiting tumor cell apoptosis and proliferation [42]. 
II.2.4.2.2. GSTπ inhibitors: 
A great deal of effort has been made in recent years to find tight inhibitors of these 
enzymes to reduce their protective function in vivo. GSTπ inhibitors may increase the 
sensitivity of cancer cells to antitumor drugs and may therefore be used for a variety of 
therapeutic applications. For such a reason, a remarkable number of inhibitors for GSTπ have 
been synthesized (Table II.2) as well as Ethacrynic acid (EA) and its analogs [52, 53]. It is the 
first clinical use of GSTπ inhibitors. Previously, it has been commonly used as a diuretic in 
clinical research for decades. In addition, various natural inhibitors present in plants have also 
been discovered and investigated. The newer TLK117 / TLK199 and NBDHEX inhibitors can 
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Table II.2 Antitumor agents targeting GSTπ in background [42] 








EA and is analogs 
 
TLK117/TLK199 
NBDHEX and its 
analogs 
GSH or GSH 
derivatives (TLK286) 
NO prodrugs (JS-K) 
Inhibiting the detoxification activity. Usually by binding to GSTπ substrate-
binding sites 
Promoting tumor-cell apoptosis by activating the MAPK pathway 
and  blocking the combination of JNK and GSTπ  
Catalyzed by GSTπto release nitrogen mustard segment to induce tumor-
cell apoptosis 
Catalyzed cy GSTπ to release high-concentration NO to kill tumor cells 
directly   
Abbreviations: GST, glutathione S-transferase; EA, ethacrynic acid; NO, nitric oxide. 
 
As already reported, GSTP1-1 is over expressed in several cancers where it protects 
cells from cell death by blocking the effects of JNK or its upstream activation. Indeed, the 
formation of both GSTP1-JNK and GSTP1-1-TRAF2 complexes has been identified in vivo 
[58]. NBDHEX (6-[7-nitro-2, 1, 3-benzoxadiazol-4-ylthio] hexanol) is designed as a 
"mechanism-based inhibitor" which has a potent effect on GSTπ. A number of compounds 
identified by ROTILI et al., containing NBD scaffolds which are not GSH peptidomimetics, 
are capable of inhibiting GSTP1-1 with a specific mechanism of action compared to other GST 
inhibitors [56].  
NBDHEX binds the GSTP1-1 H-site and forms a GSH complex to inactivate the 
enzyme (Figure II. 9). Importantly, NBDHEX is also able to isolate GSTP1-1 from its JNK and 
TRAF2 complexes, thus allowing their activation. Drug combination studies have shown that 
NBDHEX is significantly active in cisplatin-resistant human osteosarcoma cells [57]. 
 
 






Figure II. 9 GSTP1-1 function in the JNK signaling pathway.  
Monomeric GSTP1 prevents tumor cells from apoptosis by inhibiting the JNK signaling pathway via 
the development of a GSTP1-JNK-cJun complex that inhibits c-Jun phosphorilation. Under conditions 
of stress, GSTP1 can disassociate and dimerize from the complex, allowing JNK to phosphorilate c-Jun. 
This event can also be caused by a GST inhibitor NBDHEX that binds GSTP1 and induces its release 
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III.1. Generality:  
As mentioned in chapter II (Section.1), medical chemists have often struggled with the 
difficult problem of determining which compounds to synthesize. There are several ways to classify 
hits, which can then be used as a starting point for hit to lead optimization. Computer Aided Drug 
Design (CADD) techniques provide a time-consuming and economical tool for the discovery of 
novel active compounds. It is a theoretical methodology that uses computer-based techniques. This 
strategy has become the most commonly used technique to substantially reduce the number of 
compounds to be synthesized and tested in vitro by predicting which would be inactive and active. 
CADD methods can be divided into two main strategies, in which the drug target or known 
active compounds are used to find novel compounds having likely the desired effect (Figure III.1), 
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namely: (a) ligand-based methods which depend on the similarity of compounds of interest to 
active compounds, and (b) receptor-based methods which focus on the complementarity of the 
compounds of interest with the binding site of the target protein [1]. 
The computational chemist has the laudable aim of developing these two different forms of 
CADD approaches by using some kind of computer program capable of automatically evaluating 
very large compound libraries. However, the combination of different structural and ligand-based 
design techniques in drug discovery efforts has been established to be more successful than any 
single strategy, as both approaches are capable of complementing their strengths and weaknesses 
[2]. 
CADD approaches are currently very popular, trying to identify new hits in the R&D 
process for new drugs. They streamline the discovery process of new compounds, when data are 
available on one or more reference ligands, or a 3D-structure of protein–ligand complex. It is 
possible to cite numerous successful examples of these approaches, which are contributed in 
particular to the marketing of an anti-cancer drug, gefitinib (Iressa®), and LY-517717 compound, 


























Figure III.1.  Workflow of ligand -based drug design (LBDD) and structure -based drug design (SBDD). 
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III.2. Ligand-based drug design (LBDD): 
III.2.1. QSAR analysis:  
Quantitative Structure–Activity Relationship (QSAR) Analysis is one of the commonly 
used methods in ligand-based drug design processes to explain the quantitative relationship 
between structural molecular properties (descriptors) and their functions, e.g. biological activities, 
physicochemical properties, toxicity, or other kinds of activities on their molecular characteristics 
[4]. 
The structure of any chemical compound is determined by its properties. The main concept 
of QSAR is that identical or more precisely similar molecules have similar properties. In other 
words, a "small" change in the chemical structure of any compound leads to a change in their 
biological activities [5]. QSAR proposes that if a group of chemical compounds shows the same 
mechanism of action against the target, the modification of biological activity often changes 
chemical, structural and physical properties [6]. 
The basic formalism of the QSAR method will result from statistical analyses. The simple 
mathematical relationship is defined as follows (Eq III.1) [7]: 
Function = f (structural molecular or fragment properties)                Eq III.1 
During the QSAR analysis, the creation of models follows a general workflow, starting 
with dataset collection and the generation of chemical descriptors to be used as independent 
variables. After the removal of descriptors, which value varies little or not, across all molecules, 
the Multivariate study finally conducts a statistical validation of the model(s) to ensure its reliability 










Figure III.2. Flowchart of the methodology used in QSAR study. 
Currently there are more than 5000 descriptors that can be used in QSAR studies. They 
may be classified into various groups that can be derived from the chemical structure or from the 
use of suitable software, based on the various dimensions of the molecular descriptor; this could 
be divided into 2D-QSAR, 3DQSAR, 4D-QSAR, and so on. It can also generally be categorized 
as QSAR receptor-independent (RI) and QSAR receptor-dependent (RD), based on the availability 
of target receptors in the model construction process. So, this division decides the form or the 
medical modalities [9]. 
III.2.2. Object of QSAR study: 
The main objective of the QSAR study is the rational creation of a mathematical model, 
followed by an examination of the involved chemical information, in order to gain insight into the 
mechanism and behavior of the system to be studied [10].  
It is also useful in identifying alternative modes of action, in selecting useful structural 
features, in preparing new design methodologies, in developing new drugs and in helping to 
formulate new hypotheses for future research studies. As a result, QSAR reduces costs, time and 
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human capital to make the pharmaceutical product available to patients. QSAR models are also 
used in anticipation of pharmacokinetic and pharmacodynamics properties. QSAR also predicts 
properties, such as: permeability, and solubility. In this thesis, the objective of the QSAR model is 
to enable the estimation of the biological activities of unknown or novel chemicals compounds to 
provide insight into the specific and consistent chemical properties or descriptors (2D/3D) 
describing the biological activity [11]. 
III.2.3. Steps involved in QSAR study: 
The production of a good quality QSAR model depends on several factors, such as: the 
quality of biological data, the selection of descriptors and the used statistical analysis. Given the 
technical advancements and the wider availability of different statistical methods and types of 
descriptors, it is now relatively easy and straightforward to create a statistically accurate model 
[12]. 
III.2.3.1. Data collection and selection of training set: 
The process of identifying accurate, initial, meaningful and potentially useful data 
arrangement is called data mining. This can include data collection, data cleaning, data engineering, 
algorithm engineering, algorithm running, result assessment, and information utilization . At the 
time of data collection, the same test procedure must be followed to bypass inter-laboratory shifts. 
[13- 15]. In order to retrieve a good collection of QSAR data, the following steps should be 
considered, namely: 
 The number of chemical substances required should be appropriate. 
 The biological activity of the chemical substances should be evenly distributed. 
 The activity spectrum of action should be spread between the least active and extreme 
active chemical substances. 
 The list of data set should have a diversity dose response relationship [16]. 
It is critically important for any QSAR model that the training set chosen to calibrate the 
model shows a well-balanced distribution and contains representative compounds. This calibration 
can be accomplished by a systematic collection of the training set, where the key structural features 
are systematically and simultaneously varied. In addition, there should be a proper ratio between 
the number of chemical substances in the training and the test set lists. The statistical molecular 
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design, self-organizing map, clustering, selection of Kennard-Stone, exclusion of spheres, and so 
on are few of the different techniques available to divide the data into training and test sets [17]. 
III.2.3.2. Molecular Descriptors used in QSAR: 
Molecular descriptors are concepts defining the specific information of the chemical 
substances being studied. They are the result of a logical and mathematical process, which 
translates chemical information encoded within the symbolic representation of a substance into a 
useful number. The useful number should therefore be correlated with different physical properties, 
chemical reactivity or biological activity. This mathematical representation must be invariant with 
the size of the molecule and the number of atoms in order to allow modeling using statistical 
methods [18].  
There are generally different types of descriptors being used during QSAR. Descriptors 
may be classified in a number of ways, including: constitutional, topological, geometric, quantum 
chemical and physicochemical one. Therefore, the majority of QSAR scientists prefer to classify 
the types of descriptors in terms of their dimensions. In view of this element, Table III.1 offers a 
valuable example of largely used molecular descriptors depending on dimensions [5].The key 
advantage of calculating theoretical descriptors using sophisticated software is that they can be 
produced even for those compounds which are not yet synthesized [19]. Table III.1 shows 
molecular descriptors widely used depending on various dimensions. 




0D Constitutional indices, molecular property, atom, and bond count. 
1D Fragment counts, fingerprints. 
2D Topological, structural, physicochemical parameters including thermodynamic descriptors. 
3D Electronic, spatial parameters, MSA parameters, MFA parameters, RSA parameters. 




These descriptors consider induced-fit parameters and aim to establish a ligand-based virtual or 
pseudoreceptor model. These can be explained as 4D-QSAR 1 explicit representation of different 
induced-fit models. Example: flexible-protein docking. 
6D These are derived using the representation of various solvation circumstances along with the 
information obtained from 5D descriptors. They can be explained as 5D-QSAR 1 simultaneous 
consideration of different solvation models. Example: Quasar. 








III.2.3.3. Variable selection methods: 
The performance of QSAR thus depends not only on the consistency of the initial collection 
of active/inactive compounds, but also on the choice of descriptors and the capacity to produce an 
acceptable mathematical relationship [21]. 
However, a single molecule can be represented in several ways by computing thousands 
computational descriptors using many algorithms and sophisticated software. Several of these 
descriptors catch the same details at times and are directly linked to each other. Therefore, the 
selection of descriptors requires a great deal of expertise for the QSAR modeler to choose the right 
ones for model creation [22]. Models can be constructed, using all the measured descriptors, but 
there may be several explanations to choose only a subset of them, such as: 
 Prediction of model accuracy can be enhanced by eliminating obsolete and unnecessary 
descriptors. 
 The QSAR model to be developed is also easier and theoretically quicker when fewer input 
descriptors are used and the interpretability of the correlation between the descriptors and 
the observable activity may be improved. 
 If the number of selected descriptors is high relative to the number of chemical substances 
of interest, the effective number of degrees of freedom could be too large to determine the 
accurate calculation of the parameters of the QSAR model. 
 Several machine learning approaches are more time-consuming than linear in the number 
of chemical substances and/or the number of descriptors, which prevents the study of data 
sets of several hundred descriptors [23]. 
For this purpose, specializing in the QSAR modeler; descriptors with a constant value for 
all observations and descriptors with a very low variance may be omitted. Just one descriptor for 
those exhibiting a strong degree of reciprocal correlation should be maintained. Descriptors which 
display a very poor connection with the biological activity can also be omitted in order to thin the 
descriptor pool. In certain situations, an effective scaling of the descriptors might also be necessary 
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III.2.3.4. Development of QSAR model:   
After the elimination of correlated and obsolete descriptors, the next step is to pick the 
descriptors to be used in the created model. In general, methods for designing the QSAR model 
could be divided into two groups: (i) Classical variable selection and (ii) Variable selection by 
artificial intelligence algorithms [25]. The first group focuses on linear methods by considering a 
linear interaction between independent variables (descriptors) and dependent variables (biological 
activity). However, in the case of artificial intelligence methods, non-linear techniques are used to 
pick independent variables (descriptors) and help to solve some of the shortcomings of classical 
methods. The selection methods are grouped into two categories as showing in the follow section 
[26]. 
III. 2. 3. 4. 1. Linear regression: 
a. Multiple linear regression (MLR):  
MLR is one of the most common and basic methods used to create QSAR models, making 
it easy to understand the features used in model creation. In the MLR method, a linear relationship 
is formed between the compounds (activity/property/toxicity), Y, and the number of independent 
variables, X, typically molecular descriptors [27]. The simplified expression (Eq III. 2) of the MLR 
equation will be as follows: 
𝑌 = 𝑎0 + 𝑎1 × 𝑋1 + 𝑎2 × 𝑋2 + 𝑎3 × 𝑋3 + ⋯ + 𝑎𝑛 × 𝑋𝑛                         Eq III. 2 
Where X1, X2... Xn are independent variables or molecular descriptors present in the model 
with the associated regression coefficients a1, a2..., an (for molecular descriptors 1 to n) and a0 is 
the constant term of the model [28]. 
The primary drawback of MLR is that it can require collinear descriptors, which may refer 
to a regression model with incorrect regression coefficients. In contrast, the number of features 
chosen does not exceed the number of observations used for model development [29]. 
b. Partial least squares regression (PLS): 
PLS is the simplest method of quantitative multivariate modeling. It implies a linear 
relationship between two data matrices, X (dependent variables) and Y (independent variables) 
(target variable).  In comparison to MLR, PLS provides advantages such as it can be useful in the 
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study of data with highly collinear, noisy and several X variables, as well as in the simultaneous 
simulation of several target variables Y [30]. PLS is based on the premise that the analyzed system 
relies on the latent variables.  
PLS eliminates the difficulty of collinear features by removing these latent factors from a 
wide collection of descriptors, which provide the critical information needed to model the target 
(response variable). The latent variables T (known as X-score) and U (Y-score) are derived from 
the large collection of descriptors and the responses (biological activity). The obtained latent 
variable T (X-score) is used to predict the U (Y-score) and, then, the U (Y-score) is used to predict 
the response (biological activity) [31]. 
The number of latent factors used in PLS is an key factor for QSAR modeling and is 
typically accomplished by the use of cross-validation approaches, such as: n-fold cross-validation 
and leave-one-out methods, where a portion of the samples is used as a training set, while the other 
portion is set aside as a test set to verify the model which was developed from the training set [32]. 
III. 2. 3. 4. 2. Non-linear regression: 
Artificial neural networks (ANN):  
ANN are the most common and widely studied soft computing techniques. They are a 
family of mathematical models being focused on the workings of the human brain. However, in 
addition to some neurological understanding, it has been shown to be an important method for 
solving nonlinear problems in much scientific research, ranging from technology to biological 
applications [33]. To each of these entries (inputs) is associated a weight (Wi), representative of 
the forces of the connection. Each elementary processor has a unique output, which then branches 
out to supply a variable number of downstream neurons [34]. The network consists of several basic 
units called neurons, grouped in a certain topology, and connected to each other. Neurons have 
been arranged into layers. Based on their location, there are three layers so-called input layers, 
hidden layers and output layers. Each of them has separate relations and functions, namely the 
transfer function, the learning rule and the connection formula [35].  
Four procedures (Figure III.3) are done in a computer neuron. The first one is the input and 
output process, which compares the input signals from the former layer neurons, decides the 
strength of each input and transmits the output signal toward the next layer neurons. The next one 
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is the sum function, which measures the number of the cumulative input signals according to 
equation III.3 [36]: 
𝑖𝑗 = ∑ 𝑤𝑖𝑗 × 𝑜𝑖                                          Eq III.3 
 
Figure III.3. Graphical view of an artificial neural network with one input layer (comprising three 
descriptors) attached to the hidden layer with the necessary weights and the output layer. 
 
Where ij is the net entry in node j (of, say, layer λ), while oi is the output of node I in the 
previous layer (λ-1); and wji is the weight associated with nodes i and j. The third one is the 
activation function, which causes outputs to change from time to time. The overview result is 
transferred to this function before the conversion function is entered. The final factor is the transfer 
function that maps the summed input to the output value. There are many possible forms for the 
transfer function, which are threshold functions, sigmoid functions and linear functions (figure III. 
4). The sigmoid logistic function is the most used, because it represents a good compromise 









Figure III.4. Activation functions generally used for neural networks study. 
An ANN will contain a variety of hidden layers. These units are composed of a regression 
equation that transforms input information into non-linear output data. 
 In order to promote the development of alternative approaches, the OECD (Organization 
for Economic Cooperation and Development) has recently developed rules for the validation of 
QSAR/QSPR models [18, 19]. The assessment of each of the five concepts is an essential step for 
presenting models relevant to the experimental plan, which was the purpose of this study. 
 Principle 1—A defined endpoint 
 Principle 2—An unambiguous algorithm 
 Principle 3—A defined domain of applicability 
 Principle 4—Appropriate measures of goodness-of-fit, robustness and predictivity 
 Principle 5—A mechanistic interpretation, if possible [38]. 
III. 2. 3. 5. Validation of QSAR model: 
The next progress, following the development of the QSAR model, is to verify the 
acceptability and reliability of the QSAR model predictions. The evaluation of QSAR regression 
model success in fitting, robustness and external prediction is crucially important [39]. The 
requisite condition for the validity of the regression model is that the multiple correlation 
coefficients R2 is as close as possible to one and the standard error of the estimation is small; 
although the former is not essentially a very good predictor of fitness. Apart from the use of fitness 
parameters, the validation of the QSAR models consists of four major parameters [40 (1) Internal 
validation. (2) Validation by data division in training and testing samples. (3)External validation 
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applying the model to outside data. (4) Data randomization. Table III.2. Demonstrate Validation 
parameters and their threshold values. 
Table III.2. Mathematical equation of statistical validation metrics used in QSAR studies [41]. 
 




∑(𝑌𝑜𝑏𝑠 − 𝑌𝑡𝑟𝑎𝑛 ̅̅ ̅̅ ̅̅ ̅̅ ̅)2
⁄  
PRESS = ∑(𝑌𝑜𝑏𝑠 − 𝑌𝑝𝑟𝑒𝑑),  𝑆𝑆𝑌 = ∑(𝑌𝑜𝑏𝑠 − 𝑌𝑡𝑟𝑎𝑛̅̅ ̅̅ ̅̅ ̅̅ )
2 
Ytran  is the mean observed activity of the training set compounds 
R2>0.6 
R2adj 
{(𝑛 − 1)𝑅} − 𝑃
𝑛 − 𝑝 − 1⁄  
 
N est le nombre des observations (les molécules) ; est le nombre de 
variables indépendantes (les descripteurs) ; est le coefficient de 





∑(𝑌𝑜𝑏𝑠 − 𝑌𝑡𝑟𝑎𝑖 ̅̅ ̅̅ ̅̅ ̅̅ )2
⁄  
 
Yobs is the observed response, Ypred is the calculated response, n defines 






𝑛 − 𝑝 − 1
⁄  
 
Yobs is the observed response, Ycalc is the calculated response, n defines 
the total number of compounds and predictor variables is denoted as p. 




𝑛 − 𝑝 − 1⁄  
 
Yobs and Ycalc are the observed (experimental) and estimated scores 
respectively, while n is the number of compounds and p is the number 
of descriptors 




∑(𝑌𝑜𝑏𝑠 − 𝑌𝑡𝑟𝑎𝑛 ̅̅ ̅̅ ̅̅ ̅̅ ̅)2











































2 ∑ (𝑥𝑖 − 𝑥)(𝑦𝑖 − ȳ)
𝑛
𝑖=1
∑ (𝑥𝑖 − 𝑥)
2 + ∑ (𝑦𝑖 − ȳ)
2 + 𝑛(𝑥 − ȳ)𝑛𝑖=1
𝑛
𝑖=1
 CCC< 1 
 
𝑄𝑡𝑟𝑎𝑛
2 > 0.5 
𝑅𝑡𝑒𝑠𝑡








< 0.1 𝑎𝑛𝑑 
0.85 ≤ 𝑘′ ≤ 1.15 
|𝑟0
2 − 𝑟0














2 =  𝑟2 × (1 − √𝑟2 − 𝑟0
2) 
𝑟𝑚
′2 =  𝑟2 × (1 − √𝑟2 − 𝑟0
′2) 
The parametre r2 and r02 are defined as folows: 
𝑟0




2  & 𝑟0














The Yobs and Ypred values have been scaled at the beginning using the 
following formula: 
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rand r02 are the squared correlation coefficients between the observed 
and (leave-one-out) predicted values of the compounds with and 




2 × (1 − √𝑟(rank)
2 − 𝑟0 (rank)
2 )  
𝑹𝒓̅̅ ̅̅  An average of the correlation coefficient for randomized data 𝑅𝑟̅̅̅̅ <0.5 
𝑹𝒓̅̅ ̅̅ 𝟐 An average of determination coefficient for randomized data 𝑅𝑟̅̅̅̅ 2<0.5 
𝑸𝒓̅̅ ̅̅ 𝟐 
An average of leave one out cross-validated determination coefficient 
for randomized data 
𝑄𝑟̅̅̅̅ 2<0.5 





× ∑|Yobs − Ypred| 
 Good predictions: 
MAE  0.1  training 
set range, AND MAE 
3   0.2 training 
set range    
 Bad prediction: 
MAE  0.15  training 
set range; OR MAE 
training set rang MAE 
3  >0.25 training 
set range e 
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III. 2. 3. 6. Applicability domain (AD): 
 The application of every QSAR model to new compounds is indirectly limited by the fact 
that the model is derived from a certain finite set of molecules: the training set. Therefore the 
prediction of a modeled response using QSAR is only valid if the compound being predicted falls 
beyond the model AD, since it is hard to anticipate the entire universe of compounds using a 
specific QSAR model [42]. The general description of the applicability domain (AD) was coined 
by Netzeva and colleagues [43]: "The applicability domain of the QSAR model is the response and 
chemical structure space in which the model makes predictions with certain reliability". The AD is 
a valuable tool for the accurate implementation of QSAR models, while the characterization of the 
interpolation space is relevant in the definition of the AD. AD (Figure III. 5. a) is an area in the 
chemical space containing physicochemical, electronic or biological knowledge on which the 
model training set is developed [44]. Various methods are in place to assess the AD of QSAR 
models. From the QSAR publications of the last decade, the most widely used method for 
estimating interpolation regions is the leverage approach (Williams plot Figure III. 5. b). A 
compound would be found outside the applicability domain if the leverage value is greater than the 
critical value of 3p/n, where p is the number of model variables plus 1 and n is the number of 
objects used to construct the model [45].  
 
Figure III. 5. a) Schematic overview of the application domain. Every ringed dot is a single data point used 
for model training. New Chemical structures (solid dots) that fall into the inner, darker field are close enough 
to the training set and the model can be used confidently. The latest substances that fall in the white region 
are so far from the training collection that the formula can no longer be used. b) Williams' plot for the 
applicability domain of QSAR model [46].  
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III.2.2. Chemical similarity analysis 
The quest for molecular similarities is a key concept for the drug discovery based in Ligand. 
Its aim is to identify and discovery new chemical substances with identical structures and 
bioactivity to query compounds. Chemical similarity is based on the idea that two identical 
molecules are likely to share similar bioactivity and physical properties. This search strategy was 
used to narrow large datasets of chemical substances to a smaller number by measuring and 
comparing the similarity coefficients between the known active compound and the compounds 
being screened. Molecular similarity has also been used to optimize the efficacy and 
pharmacokinetic properties of lead compounds, based on their structure–activity relationship [33]. 
A number of computational chemical similarity search algorithms have been developed. Chemical 
substructure fingerprints, Non-hashed structural fingerprints, such as: MACCS keys or Obabel FP3 
are the most widely used methods [48]. 
Some forms of molecular representations have been used in similarity searches, including 
physiochemical properties, topological indices, molecular diagrams, pharmacophore 
characteristics, molecular shapes, molecular fields, and so on. When the molecular descriptors for 
the molecules of interest have been determined and the compounds translated to suitable data 
representations, the next step is to measure the chemical similarity using a distance metric. These 
metrics can be measured using one of the different methods. However, in the case of binary 
chemical fingerprints, the most common is the Dice coefficient, the Cosine coefficient, and the 
easiest and most straightforward distance calculation is the Tanimoto coefficient [49]. The 
coefficients are so-called "association" when they take, each one, their value in the interval [0; 1], 
thus making it possible, by simple subtraction, to convert a distance metric into a similarity metric 
and vice versa [50]. 
Focused on structural representation, molecular similarity techniques can be mainly divided 
as 2D or 3D similarity techniques. 2D similarity methods rely only on 2D structural knowledge 
and are among the easiest, most effective and most common similarity search methods. In order to 
overcome shortcomings associated with 2D similarity techniques, several techniques have been 
developed that account for 3D molecular conformation when performing similarity searches [51]. 
These techniques include form similarity, 3D fingerprints, field-based molecular methods and 
pharmacophore modeling, which were considered to be the most commonly used tool. A 
description of the pharmacophore modeling is included in the next section. 
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III.2.3. Ligand_ Based Pharmacophore:   
Pharmacophore simulation is another important and effective approach used today in 
CADD. This method allows researchers to conduct simulated screening on vast ligand databases 
and to accomplish the key goals of the CADD, which are meant to identify and/or design new drug 
candidates for use as new medicines or to design new drugs that are supposed to be superior to 
current treatments [52]. 
The definition of a pharmacophore was previously proposed by Pual Ehrlich in 1909. It is 
known as "a molecular framework which carries (phoros) the essential features responsible for a 
drug's (pharmacon's) biological activity" [17] This description has been revised by Peter Gund after 
a century of creation: "a set of structural features in a molecule that is recognized at a receptor site 
and is responsible for that molecule's biological activity" [18]. According to the very recent 
description of the IUPAC [2], there is a pharmacophore model "an ensemble of steric and electronic 
features that is necessary to ensure the optimal supramolecular interactions with a specific 
biological target and to trigger (or block) its biological response" [15, 39]. One which explains it 
more easily: a pharmacophore is a spatial arrangement of functional groups important for biological 
activity; a pattern arising from a collection of molecules having biological activity. As a result: 
 The pharmacophore identifies the basic, electronic and steric function identifying points 
required for an optimum relationship with the related pharmacological objective. 
 A pharmacophore is not a real combination of functional groups nor a particular compound, 
but a purely abstract term which represents for the common compounds a potential 
interaction of a group of compounds against their binding site [53]. 
Focused on the superposition of a series of inactive and active compounds, either a ligand-
based pharmacophore model may be created. The goal of these methods can be summarized as the 
recognition of important features to be found in active compounds and, therefore, not found in 
inactive compounds. In a structure-based approach, by exploring potential contact sites between 
the biological active site and the molecules, Pharmacophore methods have been widely utilized in 
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scaffold hopping, 3D database search, VS, ligand profiling, fragment modeling, pose filtering and 
pharmacological predictive activities Figure III. 6 [54]. 
Figure III.6. General framework of pharmacophore methods. 
Ligand-based pharmacophore simulation is an efficient strategy to promote drug 
development and discovery where the target structure is unknown, indicating potential 
pharmacophore queries based on a collection of aligned active chemical structures, in which the 
choice of these ligands has a high effect on the subsequent pharmacophore model. Therefore, these 
recognized ligands are compared in the next step, and the typical chemical features of their 3D 
structures are removed, reflecting the critical interaction between the compounds and the 
macromolecular structure. This technique can be used to produce a pharmacophore model from a 
variety of ligands (training set chemical structures) and typically includes the following key steps: 
(i) A collection of suitable conformers have been created for each ligand in the training set list to 
reflect conformational versatility within the DS Diverse conformation generation module, using 
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the conformational analysis, conformational algorithm, and (ii) alignment of multiple ligands in 
the training set and generation of the ligand-based pharmacophore model [21, 55] . 
 There are two different kinds of techniques which are documented in the published works 
to define the important common chemical characteristics for the design of pharmacophore models. 
Similar Features Pharmacophore Modeling [56] uses similar chemical features is found on the most 
active chemical structure; 3D QSAR Pharmacophore Modeling [57] is determined by the chemical 
properties of the most active and inactive chemical structures and their subsequent biological 
action. The 3D-QSAR technique differs from the Common Feature Pharmacophore method, since 
there is no restriction on the number of training chemical structures set and the technique does not 
need empirical biological activity measures in comparable bioassay conditions [58]. 
(iii) The final stages are the evaluation of the pharmacophore model by: Fischer's 
randomization test, cost analysis and the estimation of biological activity of the test set list. The 
performance of the model is defined in terms of fixed costs, total costs and null costs. The fixed 
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III.3. Structure-based drug design (SBDD): 
III. 3. 1. Molecular Docking:  
Many enzymes or proteins are targets for essential bioactive chemical agents in the treating 
of plant, animal and human related diseases. The interaction between biologically important small 
chemical compounds (so-called ligands) and protein or enzyme targets provides an important role 
in the maintenance of protein functions. Molecular docking is an analysis of how two or even more 
molecular structures (e.g. drugs and enzyme or proteins) interacting together [60]. Molecular 
docking is among the most widely used techniques in SBDD once 3D-target protein and binding 
site are available. This methodology is able of predicting and defining, with a high level of 
precision, the conformation and low-energy binding mode of small-molecule ligands within the 
required protein or enzyme target binding site. 
Fischer suggested first ever docking strategy for binding ligand receptor research (Figure 
III. 7) demonstrates the "lock-and-key model"[3], which corresponds to a rigid docking. Ligand 
moves into the bending site of the target as a key, and the target acts as a lock to detriment the 
perfect position for the "key" to unlock the "lock". This model underlines the significance of 
geometric complementarity [61]. Therefore, the actual docking mechanism is so fluid that targets 
and ligands need to modify their orientation to match each other well. So, computer-simulated 
ligand binding attempts to determine the current best ligand binding mode for a proteins partner. It 
consists of producing a variety of potential conformations/orientations, i.e. ligand poses, and within 
the macromolecule binding site (here just proteins are considered). The existence of the three-
dimensional structure of the protein is therefore a sufficient condition. For reliable docking 
analysis, an experimental structure (e.g. X-ray crystallography or NMR) or a structure extracted 
through computational methods (e.g. homology modeling) with high resolution is needed [62]. 
A chemical substance or ligand which is strongly joined by hydrogen bonds, van der Waal 
bonds or any potential electrostatic attractions connected with the receptor or protein target of the 
disease can block the role and then behave as a drug. Hydrogen bonds are localized electrostatic 
connections between atoms that contribute an important role in the detection of ligand binding to 
the protein. Calculation of correct protein-ligand interactions is the main concept behind structural 








Figure III.7. Enzyme Activity Model Lock-and-Key [64]. 
III.3.1.1. Theory of docking: 
Basically, the determination of the most possible binding orientations consists primarily of 
two parts: firstly, the use of a search algorithm to determine ligand orientations at the active site of 
the macromolecule, and, secondly, the scoring function, which correlates the score for each 
orientation (figure III.8). Preferably, search algorithms must be able to achieve the experimental 
interaction mode, and the score function will also be the best of all the generated orientations [65]. 
These tasks are performed by the software of this approach in a cyclical process. 
 
 





Figure III.8. Schematic explains the techniques used for protein ligand docking. 
III.3.1.2. Search algorithm: 
The algorithm can establish an optimal number of orientations where the structural 
properties of the compounds, such as torsional (dihedral), translational and rotational degrees of 
freedom, are adjusted progressively. A range of algorithms used for docking study could make the 
treatment of ligand flexible, and can be categorized into three essential categories: systematic 
methods (incremental construction, conformational search, databases); random or stochastic 
methods (Monte Carlo, genetic algorithms, tabu search); and simulation methods (molecular 
dynamics, energy minimization). The degrees of flexibility of the molecules involved in the 
calculation control the classification of molecular docking methods [66]. 
 The goal of these algorithms is to discover all the degrees of freedom in a ligand by rotating 
it from 0 to 360 ° for all single bonds using a picked incremental step. All the degrees of 
freedom of each coordinate are discussed in a combinatorial manner. As a consequence, the 
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𝑖=1                      Eq III.4 
After multiple cycles of search and assessment, the minimal energy solution 
referring to the most probable binding mode will converge (Figure III.9.b). Despite the 
good quality of this system, it can converge to a local minimum instead of a global 
minimum. This downside can be solved by running simultaneous searches beginning from 
various points of the energy landscape (i.e., distinct conformations). These strategies are 
divided up into: Exhaustive Scan, conformational Ensemble, fragmentation [67]. 
 Stochastic algorithms: Adjust the values of the degrees of freedom randomly instead of 
systematically. The benefit of these strategies is speed, so they might theoretically find an 
optimal solution quickly. As a downside, they do not guarantee that the conformational 
space is fully checked, meaning that the real solution can be lost. The absence of 
convergence is partially overcome by increasing the number of iterations of the algorithm 
[62].  
Stochastic algorithms work by creating random improvements to a specific ligand or a 
ligand group. For this purpose, the algorithm produces a series of molecular orientations 
and occupies a wide variety of energy landscapes (Figure III.9.c). This approach removes 
trapping the final solution at a minimum of local energy and raises the chance of a global 
minimum. As the algorithm supports wide coverage of the energy environment, the expense 
of processing associated with this technique is a significant constraint [33, 35]. The benefit 
of these strategies is efficiency, so they might theoretically find an optimal solution quickly. 
The most popular stochastic algorithms in the world are: Tabu search, Swarm optimization, 
Evolutionary Algorithms (EA), and Monte Carlo (MC) [67].  
 Simulation methods: Molecular Dynamics are the most popular simulation technique, a 
process that explains the evolution of the system over time. This method is accomplished 
by changing each atom independently in the region of the rest of atoms, whereas the MD 
simulation reflects the versatility of both ligand and macromolecule more accurately than 
other algorithms. A wider explanation will be given in section III.3.2. 
 
 




Figure III.9. Small-molecule conformational search methods. (A) A molecule containing two bulky groups 
(green and purple spheres) has its conformation defined by two internal dihedrals Φ1 and Φ2; (B) 
Considering Φ2 as a frozen dihedral, the energy variation due to rotation of Φ1 is plotted in a 1D energy 
landscape. The initial structure (grey spheres) is modified by changing Φ1, leading to a decrease in energy. 
The systematic search algorithm changes all structural parameters until a local (blue spheres) or global (red 
sphere) energy minimum is reached; (C) The stochastic search explores the conformational space by 
randomly generating distinct conformations, populating a broad range of the energy landscape. This 
procedure increases the probability of finding a global energy minimum [67]. 
III.3.1.3. Scoring: 
After the creation of thousands of ligand configurations, the scoring functions are another 
significant feature that needs to be discussed since they have an important role in the choice of 
poses. It is used to distinguish putative correct poses from incorrect poses produced by the sampling 
engine or binders from inactive compounds in a fair computational period. The goal of any scoring 
method is to measure the free energy change of the creation of the ligand-receptor complex pose 
[60]. This could be described by the fundamental thermodynamics (Eq III.5) given by the binding 
constant (Kd) and the free energy of Gibbs (ΔGL). 
∆𝐺 = ∆𝐻 − 𝑇∆𝑆                              Eq III.5 
Where ΔH is the enthalpy change, T is the temperature of the system in Kelvin and ΔS is the 
entropy change [68]. 
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Free-energy simulation methodologies have been improved for the computational modeling 
of protein-ligand interactions and the estimation of binding affinity. However, these costly 
measurements remain inefficient for the measurement of large quantities of protein-ligand 
complexes and are not always reliable. Scoring functions introduced in molecular docking 
programs make numerous assumptions and simplifications in the evaluation of modeled complexes 
and do not adequately account for a variety of physical processes that determine molecular 
recognition, e.g. entropic effects [68]. The conventional classification proposed by Wang et al. 
(2002) is classified into three major groups: force field-based, knowledge-based and empiric. In 
2015, Liu and Wang suggest a new classification as following: physics-based, empirical, 
knowledge-based and machine learning-based. For that study of Jin li et al. indicates that the 
conventional classification is more general and is capable of categorizing the functions of score 
according to the major development plan embraced. 
 Force field based scoring functions:  It measures binding energy by integrating energy 
concepts from the classical force field of the bond (angle bending, dihedral variation and 
bond stretching) and non-bonded terms (electrostatic and van der Waals force) using 
equations of molecular mechanics [69]. It calculates both ligand internal energy and 
protein-ligand interaction energy by the electrostatic interactions described in the Coulomb 
function and van der Waals energy described in the Lennard Jones potential, where a 
distance-dependent dielectric can be added to mimic the solvent effect. Drawbacks include 
overestimation of binding affinity and arbitrary collection of non-bonded cutoff names, and 
the benefits of force field-based score functions include solvent accounting [70]. 
 Empirical scoring functions: are designed to replicate experimental affinity data; they are 
a separate type of assessment techniques. These operations are the sum of different empiric 
energy concepts, such as apolar interactions, ionic and hydrogen bonding, as well as 
entropic effects and desolvation, etc. For a first stage in the creation of an empiric function, 
a sequence of protein-ligand aggregates with defined binding affinities are used as a training 
set list to run a multiple linear regression study. The weight constants produced by the 
statistical model are then used as coefficients to modify the terms of the equation [71]. 
 Knowledge-based scoring functions: are other techniques used to test ligand-receptor 
binding energy. These approaches use mathematical analysis of interactive atom pairs from 
protein-ligand complex structure with accessible three-dimensional structures. These 
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potentials are built by considering the frequency where two separate atoms are observed 
over a specified distance in the structural data source. The various types of interactions found 
in the dataset are categorized and weighted by their frequency of occurrence. The total score 
value is the sum of these individual interactions. As knowledge-based functions do not rely 
on reproducing linking affinities (empirical methods) or ab initio measurements (force-field 
methods), they have an adequate balance between precision and speed [72]. 
 




Scoring function formulate 



























Extended force-field-based scoring function from AutoDock. 
For two atoms i, j, the pair-wise atomic energy is evaluated by the sum of van der Waals, hydrogen 
bond, coulomb energy and desolvation. W are weight factor to calibrate the empirical free energy. 
∆𝑮 = ∆𝑮𝟎 + ∆𝑮𝒓𝒐𝒕 × 𝑵𝒓𝒐𝒕








Empirical scoring function from FlexX. 
ΔG is the estimated free energy of binding; ΔG0 is the regression constant; ΔGrot , ΔGhb , ΔGio , ΔGaro 
and ΔGlipo are regression coefficients for each corresponding free energy term; 𝒇(∆𝑹, ∆𝜶) is scaling 
function penalizing deviations from the ideal geometry; Nrot is the number of free rotate bonds that are 
immobilized in the complex. 











Knowledge-based scoring functions PMF. 
kB is the Boltzmann constant; T is the absolute temperature; r is the atom pair distance. 𝒇𝑽𝒐𝒍−𝒄𝒐𝒓𝒓
𝒋
(𝒓) is 
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III.3.1.4. Molecular docking types: 
 Rigid docking: This approach considers both ligand and protein to be like rigid structures, 
for that the search space is very small and limited. It includes only three translational and 
three rotational degrees of freedom during the searching process. This approximation is 
close to the "lock-key" binding model and is mostly used for docking protein where there 
are many orientation degrees of freedom too large to be looked for [46]. Throughout this 
case, ligand mobility may be handled with the use of a pre-computed range of ligand 
orientations or by allowing a degree of atom-atom overlap between the ligand and protein. 
In the general case of this technique, the binding site and the ligand are approximated by 
"hot" dots in these approaches and the overlap of the matching point is evaluated. 
Computations for rigid docking are easier to complete and do not reflect correct poses or 
global minimum orientation [73]. 
 Semi-flexible docking: In comparison to the previous approach, the flexibility of the ligand 
is reacquired where the orientation is changed; unlike the protein is solid entity. This type 
of docking is ideal for docking small molecules and macromolecules such as proteins or 
nucleic acids and small ligand compounds [74]. These approaches presume that the 
unaltered conformation of the protein may correspond to the one capable of recognizing the 
ligands to be docked. This hypothesis, as already stated, is not always confirmed. Since 
1980s, various docking algorithms have been developed (table III.3) [75].  
 Flexible Docking Its principle idea based on, during binding, a protein is not a passive solid 
agent and it considers ligand and protein to be flexible equivalents. During this method, the 
docking method allowed the orientation of the docking process (receptor and ligand) to be 
easily changed. In view of the fact that receptor and ligand variables rise in accordance with 
the number of atoms, multiple additional factors considerations need to be addressed. The 
fact is that the measurement is significant and that the docking procedure is too complex. 
Flexible docking is commonly used to reliably analyze the relationship (interaction) 
between compounds (generally ligand-receptor) accurately [76]. 
III.3.2. General on molecular dynamic: 
Molecular dynamics (MD) methods play a key role in understanding and forecasting the 
function, structure and properties of molecular systems. They are a crucial method for predictive 
molecular design. They were suggested in the being by Alder and Wainwright in the last of 1950s 
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to model the interactions of hard spheres. Nowadays, however, MD strategies are used to research 
almost any form of nucleic acids, macromolecule—proteins, carbohydrates—of biological or 
medicinal importance. In short, the MD approach is based on Newton's second law or the motion 




= 𝐹𝑖                        Eq III.5 
Where, Fi is the component of the net force acting on the i
th atom with a mass, mi, and  ri 




                  Eq III.6 
Where, U (ri, r2, . . ., rn) is the potential energy function of the specific conformation and 
can be described by using the concept of a force field with predefined parameters [78].  
The concept "force field" is a statistical method used to incorporate the mathematical 
formula and the related parameters. There are complicated equations, but they are easy to 
determine. It consists of an empirical form of the interatomic potential energy U, and a series of 
parameters used to characterize the energy of the protein as a function of its atomic coordinates 
[77]. The product of the MD simulation is a series of snapshots or orientations named the trajectory 
of the system after a certain period of time; typically tens to a few hundred nanoseconds. These 
snapshots can be used to explain device dynamics and to measure macroscopic properties using 
statistical mechanics principles, some of which can be directly related to experimental results [77]. 
We carry out computer simulations in the hope of understanding the properties of compounds 
assemblies in terms of their structure and the microscopic interactions between them. The key 
benefit of the MD method is its ability to simulate the laboratory conditions in which a conventional 
biological issue is answered [79]. 
In this formalism, the atoms of the system are modeled as points with a given mass and 
charge. Charges are used to measure the electrostatic force field by which the force of each atom 
in the system can be measured. The force is then used to update the position of each atom using 
classical mechanics. This method is then iterated to adjust the configuration of the system. This 
approach enables us to acquire knowledge not only on the conformations explored by protein 
systems, but also on their dynamics Figure III.10 [80].  
 
 




Figure III.10. Molecular dynamics basic algorithm. Notes: The simulation output, the trajectory, is an 
ordered list of 3N atom coordinates for each simulation time (or snapshot). Abbreviations: Epot , potential 
energy; t, simulation time; dt, iteration time; For each spatial coordinate of the N simulated atoms (i): x, 
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IV. 1.  QSAR investigations and Ligand-based virtual screening on a series of 
nitrobenzoxadiazole derivatives targeting human glutathione-S-transferases 
 
 
Figure IV. 1. The workflow used in QSAR-based virtual screening study  
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IV. 1. 1. Introduction  
For the rational design of novel GSTP1-1 inhibitors, the quantitative structure-activity 
relationship (QSAR) [1-5] has considered to be an important method for estimating the biological 
activities of molecular structure compounds and experimental data [6]. Thanks to QSAR, the 
biological properties and activities can be easily estimated in silico without any experimental effort 
for the synthesis and evaluation of potentially novel compounds [7, 8]. The secret to success in this 
type of research is the proper choice of molecular descriptors related to the biological behavior, the 
chosen statistical models and the consistency and availability of biological data [9]. Common 
QSAR approaches include partial least squares (PLS) [11], multiple linear regression (MLR) [10], 
artificial neural network (ANN) [13], genetic algorithms (GA) [12], and support vector machine 
(SVM) learning method [14]. 
The objective of this study (Figure IV. 1) is to validate an efficient strategy for the accurate 
prediction of molecular geometries and electronic properties of potentially active compounds and 
to identify the best molecular descriptors to be used in combination with the linear (MLR) and 
nonlinear (ANN) QSAR models to identify the best GSTP1 inhibition candidates. Towards this 
reason, the biological data used in this study concerned cytotoxic agents targeting human 
glutathione-S-transferases as defined by Caccuri and co-workers. [15, 16]. These authors 
researched, examined, synthesized and tested a series of 38 nitrobenzoxadiazole derivatives for 
their in vitro GSTP1-1 inhibitory activity. Their chemical compositions are shown in Table IV. 1. 
They correspond to the substituted thiol group fixed in para-position with respect to the group nitro 
of nitrobenzoxadiazole. This family of thiol-activated anticancer drugs is promising for cancer 
treatment. However, most of them are either in pre-clinical creation or clinical trial phases [17]. In-
depth studies of these compounds are therefore required. 
We began our analysis by optimizing the composition geometry of interest derivatives of 
nitrobenzoxadiazole. These optimizations are carried out at the theoretical stage of B3LYP/6-311 
++ G (d, p). Subsequently, the validation of the accuracy and reliability of the QSAR models 
adopted was carried out using the LOOCV, Y-randomization and external test set validation 
techniques. The QSAR models obtained were finally used to classify the biological activities of 
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Table IV. 1. Observed and predictive activities (and their differences) of the set of nitrobenzoxadiazole 
derivatives [15, 16]. * denotes the external test set for GSTP1-1. 
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6.523 6.470 -0.053 6.566 0.043 
 
IV. 1. 2. Methodologies:  
IV. 1. 2. 1. Equilibrium structure optimizations: 
Accurate molecular geometry predictions are subject to the choice of the electronic structure 
method and the atomic basis set used for the classification of the atoms. We began our investigations 
by selecting the necessary methods to be used to evaluate the equilibrium structures of the 
derivatives of nitrobenzoxadiazole under analysis. Our approach is to conduct benchmark 
computations on the subunit of the series. We have shown that this technique ensures a reasonable 
balance between accuracy and computational resources to describe the properties of the 
nitrobenzoxadiazole derivatives considered. In Refs,  [18, 19] benchmarks for the 2,1,3-
benzoxadiazole subunit, using semi-empirical AM1 and PM3 methods, Hartree-Fock and 
MollerPlesset (MP2) ab initio techniques, and BLYP and B3LYP DFTs, in combination with 
different base sets, are applied. When compared to experimental structural parameters, it turns out 
that B3LYP/6-311G(d, p) is accurate enough to predict a 2,1,3-benzoxadiazole balance structure. 
From this, we conclude that B3LYP, in conjunction with the 6-311++G (d, p) base set, is suitable 
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for the analysis of 2,1,3-benzoxadiazole derivatives. Thus, this stage of theory will be used for the 
estimation of the balance geometry of interest derivatives of nitrobenzoxadiazole. Geometries of 
all molecules were initially pre-optimized by molecular mechanics (MM) approach. The minimized 
structures were further optimized using the semi-empirical Austin Model 1 (AM1) method as 
implemented in HyperChem (version 7.0) [20], which was used for these calculations. In the 
optimization of geometry, an RMS gradient of 0.01 kcal Å-1 mol-1 was adopted as a convergence 
threshold. These structures were further refined, without restrictions, by using the DFT B3LYP/6-
311++G(d, p) method, which was also used to measure some theoretical descriptors, as 
implemented in Gaussian 09 [21]. The MarvinSketch [22] software was used to measure other 
molecular descriptors, such as topological ones. 
IV. 1. 2. 2. Molecular descriptors generation: 
In order to obtain reliable QSAR models, various molecular descriptors, encoding different 
molecular size, hydrophilicity [23], electronic and topological properties, were computed from 
three separate programs: MarvinSketch[22], HyperChem[20], and Gaussian[21]. The various 
molecular descriptors selected for the 2D QSAR are shown in Table IV. 2 along with their symbols 
and descriptions. The 2D and 3D MESP maps of 2,1,3-benzoxadiazole are given in Ref. [19]. Areas 
which characterized with low electrostatic potential are found around nitrogen and oxygen atoms. 
They relate to the excess of electronic charges favoring electrophilic attacks on these sites. Whereas 
the areas characterized with high potential are situated around the four hydrogen atoms of the six-
member aromatic ring (Figure IV.2). They are characteristic of an electron deficiency where 
nucleophilic attacks may occur. 











Table IV. 2. Symbols and description of all calculated molecular descriptors 
Notation Description  Notation Description  
V Volume  nrot Number of Rotatable Bonds 
MW Molecular weight Wiener  Wiener indexes  
S Surface  nC=O Number of carbonyl fragments  
Log P Partition Coefficient Qmax The highest positive partial charge on the molecule 
HE Hydration energy  Qmin The lowest negative charge on the molecule 
SAS Solvent accessible surface  HOMO The energy of the highest occupied Molecular Orbital 
Pol Polarizability  LUMO The energy of the Lowest Unoccupied Molecular Orbital 
PSA Polar Surface Area qS Charge of the Sulfur atom 
HBD Hydrogen Bond Donor µ Dipole moment  
HBA Hydrogen Bond Acceptor  E-Sol Solvation Energy  
a_hyd Number of hydrophobic atoms HF Heat of formation  
 
IV. 1. 2. 3. Model development: 
The first pre-selection of the most appropriate set of descriptors for the anti-cancer model 
operation was performed using the hierarchical cluster analysis (HCA) [24]. Within this process, a 
dendrogram is created by an iterative coupling procedure in which clusters are developed on the 
basis of similarity and grouping criteria [25]. The Pearson coefficient R was used to test the 
association between molecular descriptors and biological responses. These coefficients were used 
to evaluate the representative descriptors of each cluster, where only one with the highest 
correlation with the negative Log of the half-maximum inhibitory concentration (pIC50) was 
chosen. 
Table IV. 3. Correlation matrix for the four selected descriptors with pIC50. See Table IV. 2 for the 
definition of these descriptors. 
  
HBA HBD Qmax a_hyd VIF 
HBA 1 
   
1.677 
HBD 0.586 1 
  
1.973 
Qmax -0.441 -0.580 1 
 
1.558 
a_hyd 0.115 -0.148 0.133 1 1.103 
pIC50 -0.509 -0.313 0.484 0.579 
 
 
We used a forward selection method to produce a subset of specific low-intercorrelation 
descriptors [26]. Then, as implemented in IBM SPSS Statistics 21[28], we used the MLR [27] 
method to construct linear QSAR models. The objective of this part was to determine the optimum 
collection of descriptors which generate the most significant QSAR models linking and interpreting 
the chemical structure of small molecules with their functional activity [25]. The correlation matrix 
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for defined descriptors could be seen in Table IV. 3. The quality of the MLR approach was 
compared to that of the ANN approche, another accurate and predictive QSAR model that was well 
suited for the treatment of non-linear relations between descriptors and activity[29,30], especially 
for highly non-linear cases[31]. In particular, back propagation (BP) is the ANN algorithm used in 
this analysis [32]. All ANN analyzes were carried out with MATLAB [33]. For the validation of 
our model, we used cross-validation and validation leave-one-out (LOO) via an external test set and 
Y-randomization procedures Table IV. 4 [34–36]. Information of the validation parameters 
computed for the model are shown in Table IV. 5. 
IV. 1. 2. 4. Virtual screening: 
Thanks to developments in computational technology over the last decade, virtual screening 
has now become a useful tool for drug development, enabling rapid and accurate detection of large 
numbers of possible hit structures. Thus, by focusing only on a small number of target substances, 
the high cost of experimental research is substantially reduced [37, 38]. Molecular similarity is a 
key concept in drug modeling and medicinal chemistry [39]. This was done by implementing the 
extended connectivity fingerprints (ECFPs) scheme in this research. The molecules are represented 
in this method as binary vectors, where a molecular fragment is represented by bit. "1"and "0" 
indicate the presence or absence of a given fragment, respectively. Therefore it is possible to infer 
the similarity between two molecules by comparing the number of common bits between their 
structures via the Dice coefficient [40, 41]. 
IV. 1. 3. Results and discussion:  
IV. 1. 3. 1. Equilibrium structure of the nitrobenzoxadiazole derivatives:  
At the B3LYP/6-311++G(d,p) stage of the theory, the balance structures of the set of 
nitrobenzoxadiazole derivatives (Table IV. 1) were obtained. The comparison between these 
structures shows that the part of benzoxadiazole closely resembles the isolated part of 2,1,3-
benzoxadiazole [18,19]. 
For instance, this specific skeleton's distances and angles are O1-N2~1.355 Å; N9-
C8~1.315 Å; C8-C7~1.439 Å; C7-C6~1.38 Å; C5-C6~1.420 Å; C5-C4~1.37 Å; C4-C3~1.429 Å; 
C3- N2~1.318 Å; O1-N9~1.37 Å and O1-N9-C8~104.6°; N9-C3-C8~108.4°; N9-C8-C7~133.1°. 
In the sequence, the nitro group attached to this subunit also has the same structural characteristics. 
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The heterocyclic nitrobenzoxadiazole is thus just marginally affected by the replacement of the 
sulfur atom. 
IV. 1. 3. 2. Quantitative structure activity relationships (QSAR) study:  
 The QSAR study was done by evaluating the values of pIC50 = - Log(IC50) for the 38 
selected compounds Table IV.  2, established for their capacity to inhibit human S-transferase 
glutathione[15, 16]. As shown in Figure IV. 3, the application of hierarchical cluster analysis to the 
set of chemical descriptors has led to seven main clusters. 
 
Figure IV.3. Hierarchical cluster analysis of descriptors (dendrogram). See Table IV. 2 for the definition of 
these descriptors. The vertical red dashed line corresponds to the clipping limit that takes into account the 
minimum number of descriptor groups without losing any information necessary for the model.  
When we used HCA, descriptors were grouped according to their pair descriptors, which 
form a specific cluster and have a high correlation between each other. We have therefore chosen 
one descriptor as a representation of each cluster to prevent duplication. The representative 
descriptors were chosen so that to reduce their coefficient of correlation with descriptors 
representing other groups. Finally, these representative descriptors have been selected: a hyd, HBD, 
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HBA, Qmin, HOMO, Qmax, Log P and E-sol. This is compatible with the docking study [15], 
which proposed choosing at least the descriptors of HBD, HBA and a hyd. The data set was 
randomly split into two subsets after choosing the independent descriptors and the dependent 
variable (pIC50). The training and test data sets consist, respectively, of 28 and 10 molecular 
compounds. Multiple linear regression enables the structural descriptors to be related to the activity 
of each of the 28 compounds in order to measure quantitatively the impact of their substituents. The 
following MLR model was developed by applying the FS-SWR (Forward Selection Step Wise 
Regression): 
𝑝𝐼𝐶50 = 6.627 − (0.389 × 𝐻𝐵𝐴) + (0.258 × 𝐻𝐵𝐷) + (1.393 × 𝑄𝑚𝑎𝑥) + (0.140 ×
𝑎_ℎ𝑦𝑑)                               Eq IV.1 
Where Qmax (the highest positive partial charge on the molecule), a_hyd (number of 
hydrophobic atoms) have a positive impact, while HBD (the number of hydrogen bond donor), and 
HBA (the number of hydrogen bond acceptor) has a negative impact on the activity. 
The model was developed to estimate activity values for both training and test data sets. 
Table IV. 1 reports the observed and theoretical activities of the pIC50, as well as their variations. 
The plot of the calculated versus observed activity (Figure IV.4) shows a linear relationship, 
indicating a satisfactory internal predictability of the produced model, regardless of the method 
used (MLR or ANN). In addition, the plot of the measured residuals against the observed activity 
values in Figure IV.4 shows that the residuals are uniformly distributed along the zero axis, thereby 




















Figure IV. 4. Experimental versus calculated pIC50 values (MLR in a) and ANN in c)), and 
residuals (MLR in b) and ANN in d)). 
Multi-collinearity was observed by the measurement of the inflation variance factors (VIF) 
for the selected descriptors [42]. The corresponding VIF values and correlation matrix for each 
descriptor are shown in Table IV. 3. From this table, it can be shown that the chosen descriptors are 
practically independent, because their R coefficients are less than 0.6. Also all variables have a VIF 
value of less than 5 and demonstrate that the model does not contain any multi-collinearity and has 
a simple statistical significance. 
Table IV.4.  Random MLR Model Parameters. 
 
Average R 0.374 
Average R2 0.156 
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Further validation of the model was done by the implementation of the Y-randomization 
test. Several random shuffles of the Y vector were performed and small mean values of 0.156 for 
R2 and-0.268 for Q2 were obtained after 1,000 randomized trials, thus showing that the successful 
results (Table IV.4) of our original model were not due to a chance association or structural 
dependence of the training set. As a second step, the presence of a non-linear relationship seen 
between pIC50 and the four descriptors chosen was investigated. For this reason, a BP artificial 
neural network was built using the identified MLR descriptors as inputs. Parameter 2n+1 was used 
to calculate the number of hidden layers, where n represents the number of input layers that play a 
key role in deciding the best artificial neural network architecture [43]. After optimization, the 
architecture of the selected ANN model was 4-3-1, i.e. 4 descriptors in the first layer three neurons 
in the hidden layer, and one neurons in the output layer for the pIC50 results. The three-layer ANN 
was trained using the Levenberg–Marquardt training algorithm.  








The ANN model, built with the same descriptors as the MLR model, given the evaluation 
metrics shown in Table IV. 5. This table below lists the evaluation metrics of both models, including 
their correlation coefficient (R2), variance ratio (F), standard error (SE), root-mean-square error 
(RMSE), adjusted R2 (R2adj), leave-one cross-validated Q
2
LOO, and r2m for external validation. A 
detailed overview of r2m is available in the literature [44]. A comparative analysis between the 
values in Table IV.5 and those extracted from the MLR method confirms the enhanced performance 
of ANN over MLR, suggesting the presence of a non-linear relationship between the four selected 
descriptors and the pIC50 of the studied compounds. The higher values of R
2 and R2adj and the 
smaller root-mean-square error (RMSE) suggest that the proposed model is predictive and accurate. 
F-test values with p just under 0.005 (see Table IV.5) indicate that the model is statistically 
important. The larger Q2LOO and R
2pred and the smaller RMSEext values also show the strong 
predictive capabilities of the ANN model and demonstrate its robustness. Values of r2 greater than 
 
















2  0.795 0.828 
 𝑅𝑎𝑑𝑗
2  0.716 0.779 𝑅𝑀𝑆𝐸𝑒𝑥𝑡 0.338 0.258 
SE 0.265 0.244 𝑟𝑚
2  0.530 0.788 
F 18.019 24.835 𝑟2 − 𝑟′2 𝑟2⁄  0.007 0.020 
RMSE 0.240 0.221 𝐾′ 0.971 0.975 
𝑄𝐿𝑂𝑂
2  0.654 0.689 |𝑟0
2 − 𝑟0
′2| 0.105 0.015 
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0.5 and values of 𝑟2 − 𝑟′2 𝑟2⁄ and |𝑟0
2 − 𝑟0
′2| smaller than 0.1 and 0.3, respectively indicate the strong 
predictive efficiency of the model. 
IV. 1. 3. 3. Applicability domain of the model:  
The Applicability Domain (AD) is an area within the chemical space involving 
physicochemical, electronic or biological information on which the model training set is built. The 
molecular AD have a fundamental role in estimating the uncertainty in the similarity test between 
the substance and those used to create the model [45]. The common definition of the AD is based 
on the Eq IV.2 following to leverage values.  
ℎ𝑖 = 𝑥𝑖
𝑇(𝑋𝑇𝑋)−1           𝑥𝑖(𝑖 = 1, 2, … , 𝑛)                     Eq IV.2 
For each structure, where I is the descriptor row vector of the query compound, and X is the 
matrix of k model descriptor values for n training chemical structure [46]. Substances with h >h* 
(h* being a threshold value equal to 3p/n, where p is the number of model descriptors plus one and 
n is the number of compounds included in the training set) may be considered to be chemically 
different from the training set compounds and thus outside the AD [47]. 
Figure IV.5. Applicability domain plot for the ANN model. Horizontal lines represent ±3σ and the vertical 
dashed line represents the warning leverage (h* = 0.536). 
To view the AD of the QSAR model, William's plot is mapped (Figure IV.5). In this map, 
the AD is defined within a squared area within the standard deviation ±x (in this study x = 3; "three 
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sigma rule" [44]). Molecules with uniform residues three times larger than the standard deviation 
of the model are marked outliers.  Careful analysis of Figure IV. 5 shows that all chemicals 
compounds in the data set fall within the AD of the proposed ANN (warning leverage) model. 
Neither of the compounds have leverage values greater than the h* alert value and none of them 
have standardized residues greater than the threshold. As a result, the model shows the best 
statistical parameters and strong predictive properties and can be used with a high degree of 
confidence in this AD. 
IV. 1. 3. 4. Importance of descriptors within different QSAR models: 
A randomization technique was used to evaluate the relative value of each descriptor used 
to create the MLR and ANN models. This also helps the best molecular descriptors to be identified. 
After the models were constructed, the first column corresponding to the first descriptor used in the 
model was deleted, leaving the remaining descriptor matrix and the Y-column identical. The mean 
absolute deviations (Δmi) between the experimental and the calculated activities for all compounds 
were defined for the four descriptors. The contribution of each descriptor (Ci%) is given by the 






 ∙ 100                                                Eq IV. 3 
 Where the sum runs over the four descriptors (HBA, HBD, Qmax, a_hyd). 
Figure IV.6. Comparison of descriptors contribution in the ANN and MLR models. 
The increase in the use of scrambled descriptor values is a measure of the significance of 
the descriptor in the model, where larger increments refer to higher importance. This method has 
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been extended to all four descriptors and the findings are shown in Figure IV. 6. It follows from 
this diagram that the hydrogen bond acceptors (HBA) and the number of hydrophobic atoms (a 
hyd) descriptors are of particular importance in the MLR and ANN models. These results are 
corroborated by the association between these descriptors and the behavior (see Table IV. 3), 
suggesting that steric interactions are the prevailing forces in ligand-protein complex creation. 
IV. 1. 3 .5. Virtual Screening Application: 
 
Table IV.6. Proposed structural compounds and predicted activities. 
No. Compound 







































































































































In order to determine GSTP1-1 inhibitors, the CHEMBL database [50] was searched for 
substances with more than 70% similarity to the most active compound in the study data set  
(Compound 31, Table IV.6). The biological activity of some compounds identified in the literature 
[59] was also estimated (Compound 58-61). These molecules have a significant degree of similarity, 
as they have the identical basic skeleton as Compound 31. In a previous docking study [15], the 
successful inhibitory potency of Compound 31 against GSTP1-1 was attributed to additional 
hydrogen bond interactions between the carbonyl moiety of Compound 31 and Gln39 residues of 
GSTP1-1, and to hydrophobic interactions with its amino acids Phe8, Val35, and Gly205, which 
help to stabilize the complex. We apply the Lipinski, Veber, Ghose, and Golden Triangle rules [19] 
to get drug-like substances. Then for all compounds, molecular descriptors were produced. The 
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compounds considered. The results of the predictions were acknowledged only when the compound 
was contained inside the AD. Table IV.6 shows that all the compounds contained are h<h*, (h* = 
0.536, Figure IV.6), and the structures and activities of these compounds are stated in Table IV. 6. 
These compounds mainly lead to the para-substituted thio-nitrobenzoxadiazole discovered earlier 
by Caccuri and co-workers [15, 16]. We have also identified such compounds where thiol is in 
ortho position with respect to the nitrobenzoxadiazole nitro group and compounds where the 
nitrobenzoxadiazole six-member aromatic ring is replaced by an amine or etheroxy organic role in 
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IV.2. Combined 3D-QSAR based Virtual Screening and Molecular Docking study of cytotoxic 
agents targeting human glutathione-s transferases 
 
  
Figure IV. 7.  Schematic representation of the virtual screening process implemented in the identification 
of Top inhibitors.  
 
Filter by Lipinski’s rule of five and Veber’s rule 
Smart Filtration & ADMET Descriptor Filter 
 
Filter by Estimated activity ≤ 0.1 µM 
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IV. 2. 1. Introduction:  
Virtual screening and modeling based on pharmacophore has reached maturity and has been 
extensively reviewed in past literature, and is very well recognized in the Medicinal Chemistry 
Laboratory [52, 53]. Pharmacophores are classified as part of a molecular structure that represents 
a collection of steric and electronic features responsible for a specific biological or pharmacological 
interaction with a specific target structure and for inhibiting its biological response [54]. 
Recently, Docking tools show promising applications for hit discovery, lead optimization 
and target-based library design [55]. The state of the art molecular docking is a computational 
technique that aims to predict the non-covalent binding of a macromolecule (Receptor) obtained 
from data banks or MD simulations, etc. with a small molecule (Ligand) as a lead for further drug 
development [56]. These lead candidates can be found using a docking algorithm that attempts to 
classify the optimal binding mode of a small molecule to an active biological target site [57]. 
Molecular docking can be used to predict affinity, bound conformation and binding energy [55]. 
The aim of drug discovery is therefore to extract drugs that bind more strongly than the natural 
substrate to a given protein target [15].   
In the present investigation (Figure IV. 7), we have produced 3D QSAR-Pharmacophore 
models, beginning with a series of cytotoxic agents targeting human Glutathione-S-Transferase. 
The best pharmacophore model was validated using three different methods and then used in the 
virtual screening of the NCI chemical library data-base containing more than 200 thousand 
compounds. In addition, in order to maximize the balance of drug-like properties of selected 
molecules, several filters have been used, such as Lipinski’s rule of five and Veber’s rule, Smart 
Filtration & ADMET Descriptor, and Filter by Estimated activity ≤ 0.1 µM. Afterwards, we 
expanded our research by applying Docking-Based Virtual Screening by studying the Ligand-
receptor binding affinity to inhibit the functioning of the GST enzyme. Results such as 
Pharmacophore hypothesis, scoring, docking study, binding mode, and so on, have been determined 
and discussed in the present section. 
IV. 2. 2.   Data collection and preparation:  
Computational drug design includes ligand-based and structure-based drug design. 
Pharmacophore model has become an excellent computational tool for searching of novel Hit/Lead 
compounds in various disease areas. The 3D-QSAR method is considered as one of important 
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ligand-based pharmacophore-modeling approaches [58]. In this study, 3D-QSAR pharmacophore 
model was generated while basing on data set of 45 published compounds, which were extracted 
from European Bioinformatics Institute database CHEMBL and the literatures [15, 16, 59]. These 
compounds were tested with similar bioassay protocol to allow proper QSAR correlation. The in 
vitro bioactivity of the inhibitors collected was expressed as the concentration of the test compound 
required for 50% inhibition of GSTP1-1 enzyme, i.e., IC50. Among the 45 compounds, 16 different 
inhibitors were selected for training from 0.1 to 14 μM (table IV. 1). The remaining inhibitors have 
been taken as a test set. The selection of the two data sets of training and testing carried out in 
accordance with the following rules: 1- same binding mode and structural diversity of molecules; 
2- both data sets most cover a wide range of activities; 3- the highest active compounds are included 
in the training set, because they provide crucial information for generating pharmacophores.  
The molecular structures of all compounds have been sketched and constructed using 
Accelrys Discovery Studio 4.1 [60] from their smile format. The optimization of these structures 
were done using the steepest descent algorithm with a convergence gradient value of 0.001 kcal / 
mol and a group of representative orientations were generated by fast conformational analysis 
methods using polling minimize algorithm [61] and CHARMM force field parameters [62]. A large 
number of orientations for each compound were generated within an energy threshold of 20.0 kcal 
/ mol above the global energy minimum. 
IV. 2. 3. Results and discussion:  
IV. 2 .3 .1. Generation of pharmacophore models: 
Two types of ligand-based pharmacophore modeling are reported in literature, one of which 
is a common feature of pharmacophore modeling and the other is 3D-QSAR based pharmacophore 
modeling, which differs from the first approaches as there is a limitation of the number of training 
compounds and a requirement for experimental biological activity values predicted in similar 
bioassay conditions [63]. 
The HypoGen algorithm in Discovery Studio 4.1 (DS) from Accelrys [69] was used to 
produce a 3D-QSAR pharmacophore model, quantitatively predicting the biological activity (IC50) 
of the compounds studied against GSTP1-1. The behaviors of the study compounds ranging from 
0.1 to 14 μM in the training set were used to produce the pharmacophore models (Table IV.7). The 
resulting conformations (255 for each compound) were used to generate pharmacophoric 
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hypotheses. In order to classify the important pharmacophore features of the training set, the DS 
feature mapping was carried out, resulting in hydrogen bond donor (HBD), hydrogen bond acceptor 
feature (HBA), hydrophobic (HYD) and ring aromatic (RA) features. The HypoGen algorithm 
gives the product of the training set, their pharmacophore features, table IV. 7 display the statistical 
parameters of the 10 top-score, hypothetical pharmacophore models developed.  








RMSD R training Max fit Features R test 
1 67.40 95.31 1.05 0.96 9.83 HBA, 3HYD, RA 0.51 
2 73.00 89.71 1.35 0.94 10.19 HBA, 3HYD, RA 0.41 
3 79.29 83.43 1.60 0.91 11.33 2HBA, 3HYD 0.76 
4 79.87 82.84 1.63 0.90 9.00 HBA, 3HYD, RA 0.64 
5 80.58 82.13 1.66 0.90 9.27 HBA, 3HYD, RA 0.65 
6 81.26 81.45 1.69 0.90 9.70 HBA, 3HYD, RA 0.68 
7 81.43 81.28 1.69 0.90 9.92 HBA, 3HYD, RA 0.67 
8 81.68 81.04 0.89 1.70 9.74 HBA, 3HYD, RA 0.67 
9 81.88 80.83 1.67 0.90 7.81 HBA, 3HYD, RA 0.44 
10 81.92 80.79 1.67 0.90 7.70 2HBA, 3HYD 0.45 
Null cost = 162.712, Fixed cost = 58.5. 
 
Over these 10 models, we must pick one of them as a relevant model, with the lowest total 
score, the highest cost difference, the low RMSD value and the high correlation coefficient [7]. The 
product of the table IV. 8 Among the 10 pharmacophore models produced, the first model (Hypo1) 
had the highest cost difference of 95.31 bits and the total cost value was much closer to the fixed 
cost compared to other models. The highest cost difference value of Hypo1 means that it can 
estimate the experimental IC50 value of training compounds with a statistical significance of > 90 
per cent (figure IV.8). This model has also shown that it has the highest correlation coefficient value 
of 0.9609 and the lowest RMSD variance of 1.054, which means that it has a better ability to predict 
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Table IV.8. Experimental and estimated activity of individual training set compounds. 
 
Compound NO. IC50 value (μM) Errors Fit value Activity scale 

















































































































             Ring aromatic feature,             Hydrophobic feature,              Hydrogen bond acceptor 
feature. 
Figure IV. 8. The best HypoGen pharmacophore model, Hypo1. 
IV. 2. 3. 2. Validation of the pharmacophore model: 
The Pharmacophore model could be evaluated using different validation methods; in this 
part we perform three different validation methods: a) cost analysis, b) test set analysis, and c) 
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IV. 2. 3. 2. 1. Cost analysis: 
The cost parameter produced by HypoGen algorithm in DS such as total cost, fixed cost, 
and null cost Table IV. 7.  Hypo1 (figure IV. 8) model has the cost difference 95.31; correlation 
coefficient value 0.96 and the RMSD value 1.05 bits (Table IV. 7). 
IV. 2. 3. 2. 2. Test set analysis: 
 Following the selection of the pharmacophore model (Hypo 1), which gives positive results 
in the cost analysis, this model was validated using 29 test-set compounds, which are different from 
the training-set compounds (table IV. 8). Using the same training set preparation protocol, the test 
set was prepared and used to assess if the hypothesis was capable of predicting active compounds 
other than the training set molecules. The obtained correlation coefficient value for the test 
compounds set is 0.511 and for the training compounds set is 0.961 (Figure IV. 9). 
Figure IV. 9. Correlation graph between experimental and estimated activities in logarithmic scale for 
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IV. 2. 3. 2. 3. Fischer Randomization Method: 
 The Fisher randomization test used to testify and evaluate Hypo 1. This approach suggests 
that the pharmacophore model did not produce a random association between the behaviors studied 
and the training structures of the data set. In order to demonstrate that the Hypo1 model was not 
created by chance at a 95 % confidence level, out of a total of 19 hypotheses generated by the 14 
scramble run, there were no valid hypotheses. This was also immediately omitted from the data 
tables. None of the five remaining randomly generated hypotheses had a lower total cost than that 
of Hypo1 (figure IV. 10). This Fischer randomization result indicates clearly that Hypo1 is 
statistically robust and not randomly generated because Hypo1 represented a true correlation in the 
training set.   
 
Figure IV.10. The difference in costs between the HypoGen runs and scrambled runs. The 95% confidence 
level was selected.  
IV. 2. 3. 3. Virtual screening: 
In this part, we have successfully used virtual screening to classify novel compounds that 
enhance the function of GSTp1-1 enzymes with their ability to inhibit the formulation of chemically 
induced cancer. For this reason, we download NCI Database SDF files containing 268667 
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filtered on the basis of the Lipinski rule of five [67], the SMARTS properties of filtration and the 
ADMET properties predicted by the ADMET Descriptors of the DS [69, 70]. The best conformer 
generation method was used to produce conformers for each molecule in the NCI database, allowing 
a maximum energy of 10 kcal/mol over that of the most stable conformation. The 3D query model 
validated in the section was used to screen the dataset. The Ligand Pharmacophore Mapping option, 
which is coupled with the best/flexible search method, was used for the screening of the database 
in order to find novel hit compounds that match all the pharmacophore features. Finally, the 
collected compounds were further filtered by the criterion that the compounds had an estimated 
activity value of less than 0.1 μM.  
IV. 2. 3. 4. Molecular Docking: 
In this section, molecular docking was carried out to identify compounds that were able to 
fit well into the binding site of GST p1-1 enzyme. As well as molecular docking generates a score 
for each compound based on the binding affinities of protein-ligand complexes. The Libdock 
algorithm [70] in DS was used to perform this study. Co-crystalized structure complex of GSTp1-
1 with NBD obtained at 1.53Å was downloaded from the protein data bank (PDB ID: 3GUS) [72]. 
The active site was defined, based on the co-crystallized inhibitor, N11211. The most active 
compound structure was docked on the same active site of the GSTp1-1 protein.  The PMF 04 score 
and docking interaction of NBD were enlisted in the Table IV. 9. The score (PMF 04) of this 
compound was 31.4. The NBD inhibitor (most active compound) was able to form 5 hydrogen 
bounds with Gln 51, Gln 64, Ser 65 and Tyr108, and tree hydrophobic interaction ILE 104, ARG 
13 and PRO 53, which is shown in Figure IV. 11. The molecules which showed better PMF 04 
score than that of NBD were considered as the potential ‘hit’ GST p 1-1 poison. Overall, 41 
compounds were found to satisfy all of the parameters selected. Meticulous visual inspection and 
examination of the bindings showed 4 compounds with a better overall docking profile compared 
to the reset list of NCI. The predicted activity of the 4 lead selected molecules NCI 767370, NCI 
750299, NCI 749387 and NCI 750300 were 0.060364 μM, 0.062314 μM, 0.063227 μM and 
0.06983 μM respectively. 
 
 




Figure IV. 11. 2D Binding interaction representation of NBD most active compound with active site of 
GSTp 1-1. 
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Multidrug resistance to chemotherapy drugs represents an obstacle in human 
cancer treatment. It encouraged extensive research into the discovery of new and novel 
mechanisms that could overcome this obstacle. Many recent researches have mentioned the 
importance role of GST in diverse cellular processes as well as in conferring resistance to 
chemotherapy. For that purpose, we implemented elaborate ligand-based and structure-based 
computational workflows to explore the structural features necessary for potent inhibition of GSTp 
1-1 using 45 different inhibitors. 
In this work, the QSAR analyses were carried out using MLR and ANN methodologies. 
We have identified four critical descriptors which successfully predict the GSTP1-1 inhibitory 
activity. The results of validation indicate the accuracy and robustness of the proposed QSAR 
model. Based on the proposed QSAR model coupled with similarity search technique, we have 
identified a series of potential novel compounds. This series has been used as a primary step for 
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predicting the GSTP1-1 inhibitory activity. It is ought to test the reliability of these predictions in 
vitro. 
The next part, provided development of ligand-based pharmacophore model by 3D-QSAR 
Pharmacophore Generation protocol. The best quantitative pharmacophore (Hypo1) was chosen 
among 10 other pharmacophores. The Hypo1 model was used as a 3D query for the virtual 
screening of 268667 drug-like molecules from NCI database. By applying selective parameters 
number of molecules funnel down to 3805 hits, docked at the active sites of GSTp1-1 (PDB ID: 
3GUS) by LibDock protocol on DS. Finally, four hits were selected based on the molecular 
interaction, structure and scoring. 
In this work, we focused more on the use of computer Ligand-Based drug design. For that 
and as future work we aim to use Molecular Dynamic, one of the techniques of computer Strucrure-
Based drug design, to confirm the quality of our extracted compounds; then we will be able to test 





















Appendix A: table of calculated descriptors. 
comp pIC50 HE Pol HBA HBD PSA nrot N(C=O) q(s) µ HOMO LUMO wiener Qmin Qmax AM1_HF Pol a_hyd E_sol logP(o/w) V MW ASA
1 6.097 -17.57 28.84 5 1 102.29 8 0 -0.156 8.364 -0.257 -0.135 943 0.862 -0.724 43.503 40.530 14 -13.369 2.971 307.077 297.335 527.195
2 6.222 -14.63 26.86 4 0 82.06 3 0 -0.182 9.143 -0.259 -0.134 702 0.911 -0.496 154.486 34.394 14 -10.894 3.551 293.449 273.272 486.633
3 6 -14.07 28.69 4 0 82.06 4 0 -0.102 9.175 -0.258 -0.134 851 0.894 -0.496 148.287 37.487 15 -8.211 3.685 301.693 287.299 521.864
4 6.699 -14.19 30.53 4 0 82.06 5 0 -0.182 8.995 -0.258 -0.135 1020 0.861 -0.485 143.245 40.581 16 -13.211 3.773 321.707 301.326 531.716
5 6.301 -13.77 32.36 4 0 82.06 6 0 -0.179 9.141 -0.254 -0.132 1210 0.861 -0.483 141.057 43.674 17 -13.662 4.215 319.575 315.353 545.500
6 5.509 -17.77 29.42 6 1 119.36 4 1 -0.153 10.717 -0.255 -0.13 1035 0.89 -0.622 213.810 37.758 14 -20.162 3.226 306.052 317.281 546.316
7 5.854 -19.77 29.42 6 1 119.36 4 1 -0.168 9.417 -0.263 -0.137 1074 0.876 -0.616 67.158 37.758 14 -16.425 3.265 287.020 317.281 496.255
8 5.77 -19.52 29.42 6 1 119.36 4 1 -0.177 7.742 -0.265 -0.138 1113 0.884 -0.631 68.651 37.758 14 -14.860 3.228 284.716 317.281 496.688
9 5.745 -14.33 33.09 5 0 108.36 6 1 -0.177 8.914 -0.262 -0.136 1470 0.891 -0.562 69.307 43.945 16 -9.601 3.833 354.675 345.335 594.345
10 6.097 -19.07 30.13 5 1 125.15 4 1 -0.183 9.289 -0.263 -0.137 1113 0.899 -0.85 118.278 38.722 14 -18.192 2.494 309.326 316.297 520.857
11 5.921 -27.47 30.77 6 2 131.39 4 1 -0.168 5.599 -0.267 -0.141 1280 0.884 -0.525 115.295 39.524 14 -20.003 2.549 329.861 332.296 574.577
12 6.222 -13.44 33.8 5 0 102.37 4 1 -0.164 7.996 -0.262 -0.137 1449 0.892 -0.562 130.267 44.910 16 -17.223 3.047 329.933 344.351 557.249
13 6.301 -20.61 32.6 6 1 120.39 5 1 -0.168 7.774 -0.265 -0.138 1470 0.878 -0.504 115.223 42.618 15 -18.655 2.992 341.250 346.323 576.164
14 5.921 -18.82 39.81 7 1 129.62 6 1 -0.186 11.014 -0.262 -0.136 2654 0.862 -0.525 71.233 54.461 18 -24.517 4.082 414.963 416.414 678.978
15 6 -20.45 42.26 6 1 120.39 7 1 -0.175 8.203 -0.263 -0.138 2997 0.88 -0.528 151.489 55.845 21 -26.090 4.780 404.869 422.421 667.128
16 5.678 -22.57 34.44 6 2 131.39 6 1 -0.181 8.31 -0.263 -0.137 1684 0.895 -0.841 73.148 45.712 16 -28.447 2.156 344.086 360.350 578.221
17 6 -15.03 38.82 6 1 114.4 7 1 -0.172 8.552 -0.233 -0.137 2164 0.892 -0.792 125.241 52.863 18 -15.201 2.727 390.059 387.420 637.308
18 6.398 -21.48 31.25 6 1 119.36 5 1 -0.161 7.314 -0.268 -0.141 1298 0.883 -0.566 72.943 40.851 15 -27.148 3.316 356.958 331.308 595.967
19 6.155 -20.98 33.09 6 1 119.36 6 1 -0.173 5.09 -0.262 -0.138 1506 0.888 -0.61 49.430 43.945 16 -15.638 3.404 319.921 345.335 556.227
20 7 -20.52 45.93 6 1 120.39 9 1 -0.186 7.978 -0.259 -0.135 3794 0.907 -0.513 133.960 62.032 23 -13.829 4.956 450.175 450.475 734.730
21 5.796 -19.21 31.25 6 1 119.36 5 1 -0.101 7.652 -0.263 -0.138 1318 0.879 -0.623 59.593 40.851 15 -23.080 3.362 329.101 331.308 553.827
22 6.155 -15.23 34.92 5 0 108.36 7 1 -0.107 5.002 -0.264 -0.139 1716 0.883 -0.539 62.282 47.038 17 -17.045 3.967 361.441 359.362 629.708
23 6.699 -18.93 44.1 6 1 120.39 8 1 -0.154 6.639 -0.257 -0.139 3384 0.881 -0.601 143.939 58.939 22 -24.159 4.914 448.109 436.448 735.218
24 7 -19.37 36.27 6 1 120.39 7 1 -0.169 6.96 -0.261 -0.138 1987 0.868 -0.598 113.083 48.805 17 -15.319 3.214 365.299 374.377 602.257
25 5.77 -14.62 25.26 5 0 108.36 6 1 -0.17 8.727 -0.261 -0.137 758 0.868 -0.571 33.328 33.811 11 -11.255 1.754 264.362 283.264 474.574
26 5.745 -14.73 25.97 5 1 111.16 5 1 -0.141 8.418 -0.261 -0.137 772 0.86 -0.701 82.146 34.776 11 -25.028 1.150 306.268 282.280 535.557
27 5.161 -21.72 28.45 6 2 131.39 7 1 -0.161 9.758 -0.256 -0.138 1058 0.89 -0.852 27.793 38.672 12 -23.332 0.418 302.324 312.306 524.474
28 5.319 -12.76 30.71 6 0 102.37 5 1 -0.168 7.408 -0.252 -0.139 1180 0.865 -0.728 93.697 42.723 14 -11.051 1.153 311.738 322.345 537.035
29 5.187 -13.36 32.63 6 0 119.44 5 2 -0.173 6.461 -0.262 -0.138 1518 0.87 -0.572 48.988 45.285 14 -21.856 0.688 357.362 350.355 593.184
30 6.222 -15.97 36.51 6 1 146.69 9 2 -0.177 9.359 -0.255 -0.132 1980 0.988 -0.674 -46.980 51.316 15 -12.332 2.536 395.410 398.396 653.170
31 6.398 -18.8 40.67 6 1 146.69 10 2 -0.161 12.838 -0.254 -0.129 2778 1.044 -0.747 -3.100 55.263 18 -21.174 3.114 443.567 432.413 737.162
32 6.523 -11.03 29.27 4 0 82.06 4 0 -0.157 9.587 -0.255 -0.133 851 0.888 -0.495 97.082 41.488 15 -8.928 4.042 317.507 293.347 523.099
33 6.523 -11.16 24.54 4 0 82.06 3 0 -0.268 9.427 -0.255 -0.132 494 0.87 -0.491 94.436 33.541 12 -13.105 3.623 287.975 253.282 476.996
34 5.131 -22.54 23.98 6 2 122.52 5 0 -0.148 11.361 -0.253 -0.13 624 0.879 -0.703 19.728 32.051 11 -18.039 0.630 249.266 271.253 441.841
35 5.854 -18.41 25.17 5 1 102.29 6 0 -0.179 9.273 -0.258 -0.134 652 0.881 -0.715 56.911 34.343 12 -14.088 2.087 264.200 269.281 474.861
36 6.301 -16.95 32.51 5 1 102.29 10 0 -0.184 9.51 -0.257 -0.134 1314 0.879 -0.734 32.825 46.717 16 -10.382 3.855 359.550 325.389 617.329
37 4.852 -18.39 26.41 6 1 119.36 8 0 0.254 5.46 -0.268 -0.152 1034 0.882 -0.732 13.792 41.332 13 -16.763 0.984 325.755 313.334 565.666





Appendix B: Computer aided drug design software. 
